In another session at the San Francisco conference, David Shapiro, MD, JD, editor of Professional Liability Newsletter, said that EHRs eventually could help hospitalists reduce their medico-legal risk by offering sophisticated alerts and suggestions to help physicians avoid mistakes that might lead to patient harm. “But at the moment, EHR involves more problems than solutions,” Dr. Shapiro said.

He outlined a few of the most common issues:

• Incorrect documentation that can be preserved in perpetuity in the chart;
• Corrections;
• Under-documentation; and
• Over-documentation.
  

Dr. Shapiro cited an example of the latter, where a physician charted a full-system physical review of a patient in the emergency department, drawing upon pull-down menus on the EHR. But the patient and two companions testified in a malpractice trial that the physician spent less than a minute looking at the patient’s laceration wound—with the documentation discrepancy seriously undercutting the physician’s credibility for the jury. Dr. Shapiro said that the liability risk faced by hospitalists has not been well-described in the medical literature, where hospitalists often are bundled with “non-procedural internists,” although malpractice insurer The Doctors Company of Napa, Calif., reports that the frequency of legal complaints against hospitalists has been rising in recent years. “I have my own list of risk factors for hospitalists, based on what I review for my newsletter,” he said.

The list includes:

• Lack of familiarity between patient and hospitalist;
• Complexity of the hospital landscape;
• Problems at shift handoffs;
• Physician production pressures;
• Test results not ready at time of discharge;
• Informal “curbside” consults; and
• Questions about who is the physician of record in the hospital and when a doctor assumes responsibility for the patient’s care.

Malpractice cases are, of necessity, relatively simple and straightforward, Dr. Shapiro said, because successful negligence claims need to be persuasive to a jury. Hospitalists may assume legal responsibility for a patient’s care just by agreeing over the phone to come and perform a consult.

“If a [hospitalized] patient is getting in trouble, I recommend that you go and see the patient. If you see the patient, then it becomes an issue of your medical judgment.”

And, physicians’ honest mistakes in medical judgment are less likely to become major liability concerns. Regardless of the rising production pressures hospitalists face, he said, “ultimately, you have to figure out how to care for these patients. … Your best defense against malpractice is to practice good medicine.” TH

Larry Beresford is a freelance writer in San Francisco.

In another session at the San Francisco conference, David Shapiro, MD, JD, editor of Professional Liability Newsletter, said that EHRs eventually could help hospitalists reduce their medico-legal risk by offering sophisticated alerts and suggestions to help physicians avoid mistakes that might lead to patient harm. “But at the moment, EHR involves more problems than solutions,” Dr. Shapiro said.

He outlined a few of the most common issues:

• Incorrect documentation that can be preserved in perpetuity in the chart;
• Corrections;
• Under-documentation; and
• Over-documentation.
  

Dr. Shapiro cited an example of the latter, where a physician charted a full-system physical review of a patient in the emergency department, drawing upon pull-down menus on the EHR. But the patient and two companions testified in a malpractice trial that the physician spent less than a minute looking at the patient’s laceration wound—with the documentation discrepancy seriously undercutting the physician’s credibility for the jury. Dr. Shapiro said that the liability risk faced by hospitalists has not been well-described in the medical literature, where hospitalists often are bundled with “non-procedural internists,” although malpractice insurer The Doctors Company of Napa, Calif., reports that the frequency of legal complaints against hospitalists has been rising in recent years. “I have my own list of risk factors for hospitalists, based on what I review for my newsletter,” he said.

The list includes:

• Lack of familiarity between patient and hospitalist;
• Complexity of the hospital landscape;
• Problems at shift handoffs;
• Physician production pressures;
• Test results not ready at time of discharge;
• Informal “curbside” consults; and
• Questions about who is the physician of record in the hospital and when a doctor assumes responsibility for the patient’s care.

Malpractice cases are, of necessity, relatively simple and straightforward, Dr. Shapiro said, because successful negligence claims need to be persuasive to a jury. Hospitalists may assume legal responsibility for a patient’s care just by agreeing over the phone to come and perform a consult.

“If a [hospitalized] patient is getting in trouble, I recommend that you go and see the patient. If you see the patient, then it becomes an issue of your medical judgment.”

And, physicians’ honest mistakes in medical judgment are less likely to become major liability concerns. Regardless of the rising production pressures hospitalists face, he said, “ultimately, you have to figure out how to care for these patients. … Your best defense against malpractice is to practice good medicine.” TH

Larry Beresford is a freelance writer in San Francisco.

In another session at the San Francisco conference, David Shapiro, MD, JD, editor of Professional Liability Newsletter, said that EHRs eventually could help hospitalists reduce their medico-legal risk by offering sophisticated alerts and suggestions to help physicians avoid mistakes that might lead to patient harm. “But at the moment, EHR involves more problems than solutions,” Dr. Shapiro said.

He outlined a few of the most common issues:

• Incorrect documentation that can be preserved in perpetuity in the chart;
• Corrections;
• Under-documentation; and
• Over-documentation.
  

Dr. Shapiro cited an example of the latter, where a physician charted a full-system physical review of a patient in the emergency department, drawing upon pull-down menus on the EHR. But the patient and two companions testified in a malpractice trial that the physician spent less than a minute looking at the patient’s laceration wound—with the documentation discrepancy seriously undercutting the physician’s credibility for the jury. Dr. Shapiro said that the liability risk faced by hospitalists has not been well-described in the medical literature, where hospitalists often are bundled with “non-procedural internists,” although malpractice insurer The Doctors Company of Napa, Calif., reports that the frequency of legal complaints against hospitalists has been rising in recent years. “I have my own list of risk factors for hospitalists, based on what I review for my newsletter,” he said.

The list includes:

• Lack of familiarity between patient and hospitalist;
• Complexity of the hospital landscape;
• Problems at shift handoffs;
• Physician production pressures;
• Test results not ready at time of discharge;
• Informal “curbside” consults; and
• Questions about who is the physician of record in the hospital and when a doctor assumes responsibility for the patient’s care.

Malpractice cases are, of necessity, relatively simple and straightforward, Dr. Shapiro said, because successful negligence claims need to be persuasive to a jury. Hospitalists may assume legal responsibility for a patient’s care just by agreeing over the phone to come and perform a consult.

“If a [hospitalized] patient is getting in trouble, I recommend that you go and see the patient. If you see the patient, then it becomes an issue of your medical judgment.”

And, physicians’ honest mistakes in medical judgment are less likely to become major liability concerns. Regardless of the rising production pressures hospitalists face, he said, “ultimately, you have to figure out how to care for these patients. … Your best defense against malpractice is to practice good medicine.” TH

Larry Beresford is a freelance writer in San Francisco.

AMSTERDAM – The investigational drug cilenglitide failed to improve overall or progression-free survival when added to standard treatment in patients with newly diagnosed glioblastoma.

Overall survival, the primary endpoint of the CENTRIC study, was 26.3 months in both study arms, with more events occurring in the cilenglitide arm than in the control arm (144 vs. 138; hazard ratio, 1.021; P = .86). "We could not identify any subgroup that actually had a benefit from the addition of cilenglitide," said study investigator Dr. Roger Stupp at the multidisciplinary European cancer congresses.

Sara Freeman/IMNG Medical Media

Progression-free survival, according to independent review, was also disappointing, at 10.6 months for the cilenglitide group and 7.9 months for the control group (HR, 0.918; P = .41), reported Dr. Stupp of the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland.

These findings signal the end of the line for the drug’s development against this tumor, Dr. Stupp remarked in presenting the results of the large phase III study. "I’m not sure we are at the end of targeting integrins, but we have taken a blow with this strategy," he said.

CENTRIC was performed in 545 patients with newly diagnosed disease and a methylated promoter of the O-6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene.

The median age of enrolled patients was 58 years, with 23% aged 65 years or older. A total of 272 patients were randomized to receive cilenglitide in addition to standard chemoradiotherapy and 272 to chemoradiotherapy alone. Cilenglitide was given at an infused IV dose of 2,000 mg twice weekly. Standard chemoradiotherapy consisted of 75 mg/m² of temozolomide (TMZ), and radiotherapy consisted of a dose of 30 grays in 2-gray fractions, with maintenance TMZ (150-200 mg/m² for six cycles).

Another trial whose results were presented was the phase II CORE trial, which enrolled 265 patients with newly diagnosed glioblastoma and unmethylated MGMT. Patients were randomized into three groups: a control arm of standard chemotherapy of TMZ plus radiotherapy, and then maintenance TMZ (n = 89); a standard cilenglitide dosing arm, with patients receiving 2,000 mg twice a week in addition to chemoradiotherapy (n = 88); and an intensive dosing arm, with the dose of cilenglitide upped to 2,000 mg five times a week in addition to chemoradiotherapy (n = 88).

Contrary to the CENTRIC study results, the CORE study findings suggested there was a benefit of adding cilenglitide to standard therapy. Median overall survival was 13.4 months in the control arm, but 16.3 months in the standard cilenglitide dosing arm (hazard ratio, 0.69 vs. control). Median overall survival in the intensive treatment arm was 14.5 months (HR, 0.86 vs. control).

Sara Freeman/IMNG Medical Media

Investigator-assessed progression-free survival also suggested a benefit of adding cilenglitide.

"These findings are inconsistent with the larger, phase III CENTRIC clinical trial," said Dr. L. Burt Nabors of the University of Alabama at Birmingham, who presented the CORE findings. "This is a limited study. It was more exploratory in nature, with a sample size that was obviously smaller." He suggested that further investigations are required to look at possible biomarkers.

Commenting on the CENTRIC study, Dr. Michael Brada of University College Hospital, London, observed: "It’s been a bumpy year for randomized trials." Recent trials in glioblastoma have generally been disappointing, and the CENTRIC study results now add to the negative results.

Additional phase I/II trials are investigating the potential of cilenglitide in combination with radiotherapy and chemotherapy in patients with locally advanced non–small cell lung cancer (NCT01118676), and in combination with chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (NCT00705016).

The CENTRIC and CORE studies were sponsored by Merck. Dr. Stupp has received honoraria for consultancy work from Merck Serono, MSD-Merck, and Roche/Genentech. Dr. Nabors had no conflicts of interest to disclose. Dr. Brada has participated on advisory boards for Roche and Merck.

AMSTERDAM – The investigational drug cilenglitide failed to improve overall or progression-free survival when added to standard treatment in patients with newly diagnosed glioblastoma.

Overall survival, the primary endpoint of the CENTRIC study, was 26.3 months in both study arms, with more events occurring in the cilenglitide arm than in the control arm (144 vs. 138; hazard ratio, 1.021; P = .86). "We could not identify any subgroup that actually had a benefit from the addition of cilenglitide," said study investigator Dr. Roger Stupp at the multidisciplinary European cancer congresses.

Sara Freeman/IMNG Medical Media

Progression-free survival, according to independent review, was also disappointing, at 10.6 months for the cilenglitide group and 7.9 months for the control group (HR, 0.918; P = .41), reported Dr. Stupp of the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland.

These findings signal the end of the line for the drug’s development against this tumor, Dr. Stupp remarked in presenting the results of the large phase III study. "I’m not sure we are at the end of targeting integrins, but we have taken a blow with this strategy," he said.

CENTRIC was performed in 545 patients with newly diagnosed disease and a methylated promoter of the O-6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene.

The median age of enrolled patients was 58 years, with 23% aged 65 years or older. A total of 272 patients were randomized to receive cilenglitide in addition to standard chemoradiotherapy and 272 to chemoradiotherapy alone. Cilenglitide was given at an infused IV dose of 2,000 mg twice weekly. Standard chemoradiotherapy consisted of 75 mg/m² of temozolomide (TMZ), and radiotherapy consisted of a dose of 30 grays in 2-gray fractions, with maintenance TMZ (150-200 mg/m² for six cycles).

Another trial whose results were presented was the phase II CORE trial, which enrolled 265 patients with newly diagnosed glioblastoma and unmethylated MGMT. Patients were randomized into three groups: a control arm of standard chemotherapy of TMZ plus radiotherapy, and then maintenance TMZ (n = 89); a standard cilenglitide dosing arm, with patients receiving 2,000 mg twice a week in addition to chemoradiotherapy (n = 88); and an intensive dosing arm, with the dose of cilenglitide upped to 2,000 mg five times a week in addition to chemoradiotherapy (n = 88).

Contrary to the CENTRIC study results, the CORE study findings suggested there was a benefit of adding cilenglitide to standard therapy. Median overall survival was 13.4 months in the control arm, but 16.3 months in the standard cilenglitide dosing arm (hazard ratio, 0.69 vs. control). Median overall survival in the intensive treatment arm was 14.5 months (HR, 0.86 vs. control).

Sara Freeman/IMNG Medical Media

Investigator-assessed progression-free survival also suggested a benefit of adding cilenglitide.

"These findings are inconsistent with the larger, phase III CENTRIC clinical trial," said Dr. L. Burt Nabors of the University of Alabama at Birmingham, who presented the CORE findings. "This is a limited study. It was more exploratory in nature, with a sample size that was obviously smaller." He suggested that further investigations are required to look at possible biomarkers.

Commenting on the CENTRIC study, Dr. Michael Brada of University College Hospital, London, observed: "It’s been a bumpy year for randomized trials." Recent trials in glioblastoma have generally been disappointing, and the CENTRIC study results now add to the negative results.

Additional phase I/II trials are investigating the potential of cilenglitide in combination with radiotherapy and chemotherapy in patients with locally advanced non–small cell lung cancer (NCT01118676), and in combination with chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (NCT00705016).

The CENTRIC and CORE studies were sponsored by Merck. Dr. Stupp has received honoraria for consultancy work from Merck Serono, MSD-Merck, and Roche/Genentech. Dr. Nabors had no conflicts of interest to disclose. Dr. Brada has participated on advisory boards for Roche and Merck.

AMSTERDAM – The investigational drug cilenglitide failed to improve overall or progression-free survival when added to standard treatment in patients with newly diagnosed glioblastoma.

Overall survival, the primary endpoint of the CENTRIC study, was 26.3 months in both study arms, with more events occurring in the cilenglitide arm than in the control arm (144 vs. 138; hazard ratio, 1.021; P = .86). "We could not identify any subgroup that actually had a benefit from the addition of cilenglitide," said study investigator Dr. Roger Stupp at the multidisciplinary European cancer congresses.

Sara Freeman/IMNG Medical Media

Progression-free survival, according to independent review, was also disappointing, at 10.6 months for the cilenglitide group and 7.9 months for the control group (HR, 0.918; P = .41), reported Dr. Stupp of the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland.

These findings signal the end of the line for the drug’s development against this tumor, Dr. Stupp remarked in presenting the results of the large phase III study. "I’m not sure we are at the end of targeting integrins, but we have taken a blow with this strategy," he said.

CENTRIC was performed in 545 patients with newly diagnosed disease and a methylated promoter of the O-6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene.

The median age of enrolled patients was 58 years, with 23% aged 65 years or older. A total of 272 patients were randomized to receive cilenglitide in addition to standard chemoradiotherapy and 272 to chemoradiotherapy alone. Cilenglitide was given at an infused IV dose of 2,000 mg twice weekly. Standard chemoradiotherapy consisted of 75 mg/m² of temozolomide (TMZ), and radiotherapy consisted of a dose of 30 grays in 2-gray fractions, with maintenance TMZ (150-200 mg/m² for six cycles).

Another trial whose results were presented was the phase II CORE trial, which enrolled 265 patients with newly diagnosed glioblastoma and unmethylated MGMT. Patients were randomized into three groups: a control arm of standard chemotherapy of TMZ plus radiotherapy, and then maintenance TMZ (n = 89); a standard cilenglitide dosing arm, with patients receiving 2,000 mg twice a week in addition to chemoradiotherapy (n = 88); and an intensive dosing arm, with the dose of cilenglitide upped to 2,000 mg five times a week in addition to chemoradiotherapy (n = 88).

Contrary to the CENTRIC study results, the CORE study findings suggested there was a benefit of adding cilenglitide to standard therapy. Median overall survival was 13.4 months in the control arm, but 16.3 months in the standard cilenglitide dosing arm (hazard ratio, 0.69 vs. control). Median overall survival in the intensive treatment arm was 14.5 months (HR, 0.86 vs. control).

Sara Freeman/IMNG Medical Media

Investigator-assessed progression-free survival also suggested a benefit of adding cilenglitide.

"These findings are inconsistent with the larger, phase III CENTRIC clinical trial," said Dr. L. Burt Nabors of the University of Alabama at Birmingham, who presented the CORE findings. "This is a limited study. It was more exploratory in nature, with a sample size that was obviously smaller." He suggested that further investigations are required to look at possible biomarkers.

Commenting on the CENTRIC study, Dr. Michael Brada of University College Hospital, London, observed: "It’s been a bumpy year for randomized trials." Recent trials in glioblastoma have generally been disappointing, and the CENTRIC study results now add to the negative results.

Additional phase I/II trials are investigating the potential of cilenglitide in combination with radiotherapy and chemotherapy in patients with locally advanced non–small cell lung cancer (NCT01118676), and in combination with chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (NCT00705016).

The CENTRIC and CORE studies were sponsored by Merck. Dr. Stupp has received honoraria for consultancy work from Merck Serono, MSD-Merck, and Roche/Genentech. Dr. Nabors had no conflicts of interest to disclose. Dr. Brada has participated on advisory boards for Roche and Merck.

SAN DIEGO – A high percentage of gout patients treated by rheumatologists do not meet the treatment goals established by the American College of Rheumatology, even after 6 months of higher-dose urate-lowering therapy, results from a national survey found.

"These findings suggest that even among rheumatologists, gout management may not be optimal and may be inadequately aggressive in the most severe patients," Dr. Max Hamburger said at the annual meeting of the American College of Rheumatology. "It seems that there is further study needed to determine the long-term impact of the new ACR guidelines."

In 2012 the ACR published updated guidelines for the management of gout and hyperuricemia (Arth. Care and Res. 2012;64:1431-46). The recommendations included a call for treat-to-target serum uric acid (sUA) of below 6 mg/dL at a minimum, and below 5 mg/dL in select patients. "The intent of this treat-to-target was to durably improve signs and symptoms of gout and also to address palpable and visible tophi," said Dr. Hamburger, a rheumatologist who practices in Melville, N.Y. "The extent to which current practice among rheumatologists aligns with the guidelines is unknown. The areas in which the guidelines may help improve gout treatment also remains to be determined."

He and his associates set out to assess symptoms, treatment, and outcomes among gout patients treated by rheumatologists in the United States and to identify gaps that might exist in current practice with the new ACR recommendations. They recruited a national sample of rheumatologists to report gout patient encounters prospectively during Jan. 15 to Feb. 22, 2013. Rheumatologists were eligible for the study if they were board certified or board eligible in rheumatology, if they spent at least 70% of their time on patient care, if they were in practice for at least 2 years, and if they saw at least four gout patients per month.

The researchers collected anonymous patient data, including demographics, history with the rheumatology practice, gout symptoms and severity, rheumatologist assessment of disease control, and gout medications and treatment changes at the time of each visit. They applied the ACR working case scenarios and grouped patients by increasing level of disease severity. Patients in the scenarios 1-3 group had intermittent symptoms and no tophi (mild disease); patients in the scenarios 4-6 group had intermittent symptoms and 1 tophus or more (moderate disease), and patients in the scenarios 7-9 group had chronic tophaceous gouty arthropathy (more severe disease). Higher-dose ULT was defined as greater than 300 mg/day of allopurinol or 80 mg or more per day of febuxostat (Uloric).

Dr. Hamburger reported results from 127 rheumatologists who received 2,380 valid patient encounter forms. Most of the patients (79%) were male, their mean age was 61 years, and 72% were seen by a rheumatologist for 6 months or longer. Based on ACR scenario groupings, 68% were in the scenarios 1-3 group, 4% were in the scenarios 4-6 group, and 28% were in the scenarios 7-9 group.

Most patients in the scenarios 1-3 group were judged by the rheumatologists to have controlled disease, compared with 91% of patients in the scenarios 4-6 group and 81% of patients in the scenarios 7-9 group. In addition, 14% of patients in the scenarios 1-3 group were on higher-dose ULT, compared with 28% in the scenarios 4-6 group and 40% in the scenarios 7-9 group. Nearly one-quarter of all patients (24%) were on higher-dose ULT.

Among patients on higher-dose ULT, 45% of those in the scenarios 1-3 group had an sUA greater than 6 mg/dL, compared with 53% in the scenarios 4-6 group and 61% in the scenarios 7-9 group. "Despite elevated sUA, 45% of encounters did not result in an increased ULT dose or treatment change at this visit," Dr. Hamburger said.

Even with 6 months or more at higher-dose ULT, only 55% of patients overall had an sUA at or below guideline recommendations of 6 mg/dL, including only 40% of patients in the scenarios 7-9 group. In addition, 16% of patients overall had an sUA between 6 and 6.8 mg/dL, despite being on higher-dose ULT for 6 months or longer.

Dr. Hamburger acknowledged certain limitations of the study, including the fact that "rheumatologist participation in this market research may be biased based on willingness to participate in online data collection over the reporting period," he said. In addition, "a varying number of encounter forms were provided by each participant and based on estimated patient volume. Not all participants reported on 100% of their patients during the reporting period."

Dr. Hamburger disclosed that he is a speaker for Savient Pharmaceuticals, which markets the gout drug pegloticase (Krystexxa), and Takeda Pharmaceuticals, which markets febuxostat and colchicine (Colcrys). Funding for the market research used in the study was provided by Savient.

[email protected]

SAN DIEGO – A high percentage of gout patients treated by rheumatologists do not meet the treatment goals established by the American College of Rheumatology, even after 6 months of higher-dose urate-lowering therapy, results from a national survey found.

"These findings suggest that even among rheumatologists, gout management may not be optimal and may be inadequately aggressive in the most severe patients," Dr. Max Hamburger said at the annual meeting of the American College of Rheumatology. "It seems that there is further study needed to determine the long-term impact of the new ACR guidelines."

In 2012 the ACR published updated guidelines for the management of gout and hyperuricemia (Arth. Care and Res. 2012;64:1431-46). The recommendations included a call for treat-to-target serum uric acid (sUA) of below 6 mg/dL at a minimum, and below 5 mg/dL in select patients. "The intent of this treat-to-target was to durably improve signs and symptoms of gout and also to address palpable and visible tophi," said Dr. Hamburger, a rheumatologist who practices in Melville, N.Y. "The extent to which current practice among rheumatologists aligns with the guidelines is unknown. The areas in which the guidelines may help improve gout treatment also remains to be determined."

He and his associates set out to assess symptoms, treatment, and outcomes among gout patients treated by rheumatologists in the United States and to identify gaps that might exist in current practice with the new ACR recommendations. They recruited a national sample of rheumatologists to report gout patient encounters prospectively during Jan. 15 to Feb. 22, 2013. Rheumatologists were eligible for the study if they were board certified or board eligible in rheumatology, if they spent at least 70% of their time on patient care, if they were in practice for at least 2 years, and if they saw at least four gout patients per month.

The researchers collected anonymous patient data, including demographics, history with the rheumatology practice, gout symptoms and severity, rheumatologist assessment of disease control, and gout medications and treatment changes at the time of each visit. They applied the ACR working case scenarios and grouped patients by increasing level of disease severity. Patients in the scenarios 1-3 group had intermittent symptoms and no tophi (mild disease); patients in the scenarios 4-6 group had intermittent symptoms and 1 tophus or more (moderate disease), and patients in the scenarios 7-9 group had chronic tophaceous gouty arthropathy (more severe disease). Higher-dose ULT was defined as greater than 300 mg/day of allopurinol or 80 mg or more per day of febuxostat (Uloric).

Dr. Hamburger reported results from 127 rheumatologists who received 2,380 valid patient encounter forms. Most of the patients (79%) were male, their mean age was 61 years, and 72% were seen by a rheumatologist for 6 months or longer. Based on ACR scenario groupings, 68% were in the scenarios 1-3 group, 4% were in the scenarios 4-6 group, and 28% were in the scenarios 7-9 group.

Most patients in the scenarios 1-3 group were judged by the rheumatologists to have controlled disease, compared with 91% of patients in the scenarios 4-6 group and 81% of patients in the scenarios 7-9 group. In addition, 14% of patients in the scenarios 1-3 group were on higher-dose ULT, compared with 28% in the scenarios 4-6 group and 40% in the scenarios 7-9 group. Nearly one-quarter of all patients (24%) were on higher-dose ULT.

Among patients on higher-dose ULT, 45% of those in the scenarios 1-3 group had an sUA greater than 6 mg/dL, compared with 53% in the scenarios 4-6 group and 61% in the scenarios 7-9 group. "Despite elevated sUA, 45% of encounters did not result in an increased ULT dose or treatment change at this visit," Dr. Hamburger said.

Even with 6 months or more at higher-dose ULT, only 55% of patients overall had an sUA at or below guideline recommendations of 6 mg/dL, including only 40% of patients in the scenarios 7-9 group. In addition, 16% of patients overall had an sUA between 6 and 6.8 mg/dL, despite being on higher-dose ULT for 6 months or longer.

Dr. Hamburger acknowledged certain limitations of the study, including the fact that "rheumatologist participation in this market research may be biased based on willingness to participate in online data collection over the reporting period," he said. In addition, "a varying number of encounter forms were provided by each participant and based on estimated patient volume. Not all participants reported on 100% of their patients during the reporting period."

Dr. Hamburger disclosed that he is a speaker for Savient Pharmaceuticals, which markets the gout drug pegloticase (Krystexxa), and Takeda Pharmaceuticals, which markets febuxostat and colchicine (Colcrys). Funding for the market research used in the study was provided by Savient.

[email protected]

SAN DIEGO – A high percentage of gout patients treated by rheumatologists do not meet the treatment goals established by the American College of Rheumatology, even after 6 months of higher-dose urate-lowering therapy, results from a national survey found.

"These findings suggest that even among rheumatologists, gout management may not be optimal and may be inadequately aggressive in the most severe patients," Dr. Max Hamburger said at the annual meeting of the American College of Rheumatology. "It seems that there is further study needed to determine the long-term impact of the new ACR guidelines."

In 2012 the ACR published updated guidelines for the management of gout and hyperuricemia (Arth. Care and Res. 2012;64:1431-46). The recommendations included a call for treat-to-target serum uric acid (sUA) of below 6 mg/dL at a minimum, and below 5 mg/dL in select patients. "The intent of this treat-to-target was to durably improve signs and symptoms of gout and also to address palpable and visible tophi," said Dr. Hamburger, a rheumatologist who practices in Melville, N.Y. "The extent to which current practice among rheumatologists aligns with the guidelines is unknown. The areas in which the guidelines may help improve gout treatment also remains to be determined."

He and his associates set out to assess symptoms, treatment, and outcomes among gout patients treated by rheumatologists in the United States and to identify gaps that might exist in current practice with the new ACR recommendations. They recruited a national sample of rheumatologists to report gout patient encounters prospectively during Jan. 15 to Feb. 22, 2013. Rheumatologists were eligible for the study if they were board certified or board eligible in rheumatology, if they spent at least 70% of their time on patient care, if they were in practice for at least 2 years, and if they saw at least four gout patients per month.

The researchers collected anonymous patient data, including demographics, history with the rheumatology practice, gout symptoms and severity, rheumatologist assessment of disease control, and gout medications and treatment changes at the time of each visit. They applied the ACR working case scenarios and grouped patients by increasing level of disease severity. Patients in the scenarios 1-3 group had intermittent symptoms and no tophi (mild disease); patients in the scenarios 4-6 group had intermittent symptoms and 1 tophus or more (moderate disease), and patients in the scenarios 7-9 group had chronic tophaceous gouty arthropathy (more severe disease). Higher-dose ULT was defined as greater than 300 mg/day of allopurinol or 80 mg or more per day of febuxostat (Uloric).

Dr. Hamburger reported results from 127 rheumatologists who received 2,380 valid patient encounter forms. Most of the patients (79%) were male, their mean age was 61 years, and 72% were seen by a rheumatologist for 6 months or longer. Based on ACR scenario groupings, 68% were in the scenarios 1-3 group, 4% were in the scenarios 4-6 group, and 28% were in the scenarios 7-9 group.

Most patients in the scenarios 1-3 group were judged by the rheumatologists to have controlled disease, compared with 91% of patients in the scenarios 4-6 group and 81% of patients in the scenarios 7-9 group. In addition, 14% of patients in the scenarios 1-3 group were on higher-dose ULT, compared with 28% in the scenarios 4-6 group and 40% in the scenarios 7-9 group. Nearly one-quarter of all patients (24%) were on higher-dose ULT.

Among patients on higher-dose ULT, 45% of those in the scenarios 1-3 group had an sUA greater than 6 mg/dL, compared with 53% in the scenarios 4-6 group and 61% in the scenarios 7-9 group. "Despite elevated sUA, 45% of encounters did not result in an increased ULT dose or treatment change at this visit," Dr. Hamburger said.

Even with 6 months or more at higher-dose ULT, only 55% of patients overall had an sUA at or below guideline recommendations of 6 mg/dL, including only 40% of patients in the scenarios 7-9 group. In addition, 16% of patients overall had an sUA between 6 and 6.8 mg/dL, despite being on higher-dose ULT for 6 months or longer.

Dr. Hamburger acknowledged certain limitations of the study, including the fact that "rheumatologist participation in this market research may be biased based on willingness to participate in online data collection over the reporting period," he said. In addition, "a varying number of encounter forms were provided by each participant and based on estimated patient volume. Not all participants reported on 100% of their patients during the reporting period."

Dr. Hamburger disclosed that he is a speaker for Savient Pharmaceuticals, which markets the gout drug pegloticase (Krystexxa), and Takeda Pharmaceuticals, which markets febuxostat and colchicine (Colcrys). Funding for the market research used in the study was provided by Savient.

[email protected]

The overall success of total knee arthroplasty (TKA) depends on proper implant choice, meticulous surgical technique, appropriate patient selection, and
effective postoperative rehabilitation. Inappropriate technique leads to suboptimal placement of implants in coronal, sagittal, or axial planes.^1-3 This results in eccentric prosthetic loading, which may contribute to accelerated polyethylene wear, early component loosening, higher rates of revision surgery, and unsatisfactory clinical outcomes. The need to optimize component positioning during TKA stimulated the development of computer-assisted navigation in TKA in the late 1990’s. Proponents of this technology believe that it helps to reduce outliers, improves coronal, sagittal, and rotational alignment, and optimizes flexion and extension gap-balancing. This is believed to result in improved implant survival and better functional outcomes. However, despite these postulated advantages, less than 5% of surgeons in the United States currently use navigation during TKA perhaps due to concerns of costs, increased operating time, learn- ing curve issues, and lack of improvement in functional outcomes at mid-term follow-up.
Navigated TKA, due to its accuracy and low margins of error, has the potential to reduce component malalignment to within 1o to 2o of neutral mechanical axis.⁴ However, others have reported that alignment of the femoral and tibial components achieved with computer navigation is not different than TKA using conventional techniques.^5-12 This lack of improvement reported in these studies may be due to a number of potential sources of errors, which can be either surgeon- or device-related. These errors may pre-dispose to discrepancies between alignments calculated by the computer and the actual position of the implants. Apart from software- and hardware-related calibration issues, the majority of inaccuracies, which are often surgeon-related, result from registration of anatomical landmarks, pin array movements after registration, incorrect bone cuts despite accurate jig placement, and incorrect placement of final components during cementation. Of these surgeon-related factors, variability in the identification of the anatomical landmarks appears to be critical and occurs due to anatomical variations or from inaccurate recognition of intraoperative bony landmarks. A recent study found that registration of the distal femoral epicondyles was more likely to be inaccurate than other anatomical landmarks, as it was found that a small change of 2 mm in the sagittal plane can lead to a 1o change in the femoral component rotation.¹³

Nevertheless, the general consensus from recent high- level evidence (Level I and II) suggests that navigated TKA leads to improved coronal-alignment outcomes and reduced numbers of outliers.^14-18 In a recent systematic review of 27 randomized controlled trials of 2541 patients, Hetaimish and colleagues19 compared the alignment outcomes of navigated with conventional TKA. The authors found that the navigated cohort had a significantly lower risk of producing a mechanical axis deviation of greater than 3o, compared with conventional TKA (relative risk [RR] = 0.37; P<.001). The femoral and tibial, coronal and sagittal malalignment (>3o) were also found to be significantly lower with navigated TKA, compared with conventional techniques. However, no substantial differences were found in the rotation alignment of the femoral component between the 2 comparison cohorts (navigated group, 18.8%; conventional group, 14.5%).

Advocates of navigation believe that improved component alignment would lead to better functional outcomes and lower revision rates.^20,21 However, at short- to mid-term follow-up, most studies have failed to show any substantial benefits in terms of functional outcomes, revision rates, patient satisfaction, or patient-perceived quality-of-life, when comparing computer-assisted navigation to conventional techniques.^11,22-25 Recent systematic reviews by Zamora et al²⁴ and Burnett et al25 found no significant differences in the functional outcomes between navigated and conventional TKA (P>.05). This lack of the expected improvement in functional outcomes reported in various studies with navigation could be due to variability in registration of anatomical landmarks leading to errors in the rotational axis, or a lack of complete understanding of the interplay of alignment, ligament balance, in vivo joint loading and kinematics. In a report from the Mayo Clinic,²⁶ the authors believed that there may be little practical value in relying on a mechanical alignment of ±3o from neutral as an isolated variable in predicting the longevity of modern TKA. In addition, they suggested that factors apart from mechanical alignment may have a more profound impact on implant durability.

Several studies^27-31 that compared the joint line changes or ligament balance between navigated and conventional TKA, report no substantial differences in the maintenance of the joint line, quality of life, and functional outcomes. Despite claims of decreased blood loss, length-of stay, cardiac complications, and lower risks of fat embolism with computer-assisted navigation by some authors, other reports have failed to demonstrate any substantial advantages, therefore, it is controversial if any clear benefit exists.^6,32-34 It is postulated that the high initial institutional costs of navigation can even out in the long run if the goals of improved survivorship and functional outcomes are achieved.³⁵ However, as mid-term follow-up studies have failed to show a survival or functional benefit, the purported costs savings from computer navigation may not be accurate. Navigated TKA has been reported to increase operative time by about 15 to 20 minutes, compared with conventional TKA. Although, this increases operative time, it has not been reported to increase the risk of deep prosthetic joint infections.

Navigation provides some benefits in terms of radiological alignment. However, the clinical advantages are yet to be defined. Currently, there are many unanswered ques- tions concerning alignment in TKA, such as having a more individual approach based on the patients’ own anatomic variations including considerations about the presence of constitutional varus in patients. Navigation may have a role when TKA is performed for complex deformities, fractures, or in the presence of retained implants that prevent the use of conventional guides. Nevertheless, one should always keep in mind cost considerations. This has been true with any technological advancement we have had in the past and will be of concern in the future as well, especially with rising healthcare costs. When analyzing costs with naviga- tion, one must take in to account not only the overall costs of technology, but also the added costs of training, increased operating room times, and disposables when performing these procedures. Although we are advocates of change and are excited about this technology, the cost-benefit ratio for computer navigated TKA needs to be reconciled.

The overall success of total knee arthroplasty (TKA) depends on proper implant choice, meticulous surgical technique, appropriate patient selection, and
effective postoperative rehabilitation. Inappropriate technique leads to suboptimal placement of implants in coronal, sagittal, or axial planes.^1-3 This results in eccentric prosthetic loading, which may contribute to accelerated polyethylene wear, early component loosening, higher rates of revision surgery, and unsatisfactory clinical outcomes. The need to optimize component positioning during TKA stimulated the development of computer-assisted navigation in TKA in the late 1990’s. Proponents of this technology believe that it helps to reduce outliers, improves coronal, sagittal, and rotational alignment, and optimizes flexion and extension gap-balancing. This is believed to result in improved implant survival and better functional outcomes. However, despite these postulated advantages, less than 5% of surgeons in the United States currently use navigation during TKA perhaps due to concerns of costs, increased operating time, learn- ing curve issues, and lack of improvement in functional outcomes at mid-term follow-up.
Navigated TKA, due to its accuracy and low margins of error, has the potential to reduce component malalignment to within 1o to 2o of neutral mechanical axis.⁴ However, others have reported that alignment of the femoral and tibial components achieved with computer navigation is not different than TKA using conventional techniques.^5-12 This lack of improvement reported in these studies may be due to a number of potential sources of errors, which can be either surgeon- or device-related. These errors may pre-dispose to discrepancies between alignments calculated by the computer and the actual position of the implants. Apart from software- and hardware-related calibration issues, the majority of inaccuracies, which are often surgeon-related, result from registration of anatomical landmarks, pin array movements after registration, incorrect bone cuts despite accurate jig placement, and incorrect placement of final components during cementation. Of these surgeon-related factors, variability in the identification of the anatomical landmarks appears to be critical and occurs due to anatomical variations or from inaccurate recognition of intraoperative bony landmarks. A recent study found that registration of the distal femoral epicondyles was more likely to be inaccurate than other anatomical landmarks, as it was found that a small change of 2 mm in the sagittal plane can lead to a 1o change in the femoral component rotation.¹³

Nevertheless, the general consensus from recent high- level evidence (Level I and II) suggests that navigated TKA leads to improved coronal-alignment outcomes and reduced numbers of outliers.^14-18 In a recent systematic review of 27 randomized controlled trials of 2541 patients, Hetaimish and colleagues19 compared the alignment outcomes of navigated with conventional TKA. The authors found that the navigated cohort had a significantly lower risk of producing a mechanical axis deviation of greater than 3o, compared with conventional TKA (relative risk [RR] = 0.37; P<.001). The femoral and tibial, coronal and sagittal malalignment (>3o) were also found to be significantly lower with navigated TKA, compared with conventional techniques. However, no substantial differences were found in the rotation alignment of the femoral component between the 2 comparison cohorts (navigated group, 18.8%; conventional group, 14.5%).

Advocates of navigation believe that improved component alignment would lead to better functional outcomes and lower revision rates.^20,21 However, at short- to mid-term follow-up, most studies have failed to show any substantial benefits in terms of functional outcomes, revision rates, patient satisfaction, or patient-perceived quality-of-life, when comparing computer-assisted navigation to conventional techniques.^11,22-25 Recent systematic reviews by Zamora et al²⁴ and Burnett et al25 found no significant differences in the functional outcomes between navigated and conventional TKA (P>.05). This lack of the expected improvement in functional outcomes reported in various studies with navigation could be due to variability in registration of anatomical landmarks leading to errors in the rotational axis, or a lack of complete understanding of the interplay of alignment, ligament balance, in vivo joint loading and kinematics. In a report from the Mayo Clinic,²⁶ the authors believed that there may be little practical value in relying on a mechanical alignment of ±3o from neutral as an isolated variable in predicting the longevity of modern TKA. In addition, they suggested that factors apart from mechanical alignment may have a more profound impact on implant durability.

Several studies^27-31 that compared the joint line changes or ligament balance between navigated and conventional TKA, report no substantial differences in the maintenance of the joint line, quality of life, and functional outcomes. Despite claims of decreased blood loss, length-of stay, cardiac complications, and lower risks of fat embolism with computer-assisted navigation by some authors, other reports have failed to demonstrate any substantial advantages, therefore, it is controversial if any clear benefit exists.^6,32-34 It is postulated that the high initial institutional costs of navigation can even out in the long run if the goals of improved survivorship and functional outcomes are achieved.³⁵ However, as mid-term follow-up studies have failed to show a survival or functional benefit, the purported costs savings from computer navigation may not be accurate. Navigated TKA has been reported to increase operative time by about 15 to 20 minutes, compared with conventional TKA. Although, this increases operative time, it has not been reported to increase the risk of deep prosthetic joint infections.

Navigation provides some benefits in terms of radiological alignment. However, the clinical advantages are yet to be defined. Currently, there are many unanswered ques- tions concerning alignment in TKA, such as having a more individual approach based on the patients’ own anatomic variations including considerations about the presence of constitutional varus in patients. Navigation may have a role when TKA is performed for complex deformities, fractures, or in the presence of retained implants that prevent the use of conventional guides. Nevertheless, one should always keep in mind cost considerations. This has been true with any technological advancement we have had in the past and will be of concern in the future as well, especially with rising healthcare costs. When analyzing costs with naviga- tion, one must take in to account not only the overall costs of technology, but also the added costs of training, increased operating room times, and disposables when performing these procedures. Although we are advocates of change and are excited about this technology, the cost-benefit ratio for computer navigated TKA needs to be reconciled.

The overall success of total knee arthroplasty (TKA) depends on proper implant choice, meticulous surgical technique, appropriate patient selection, and
effective postoperative rehabilitation. Inappropriate technique leads to suboptimal placement of implants in coronal, sagittal, or axial planes.^1-3 This results in eccentric prosthetic loading, which may contribute to accelerated polyethylene wear, early component loosening, higher rates of revision surgery, and unsatisfactory clinical outcomes. The need to optimize component positioning during TKA stimulated the development of computer-assisted navigation in TKA in the late 1990’s. Proponents of this technology believe that it helps to reduce outliers, improves coronal, sagittal, and rotational alignment, and optimizes flexion and extension gap-balancing. This is believed to result in improved implant survival and better functional outcomes. However, despite these postulated advantages, less than 5% of surgeons in the United States currently use navigation during TKA perhaps due to concerns of costs, increased operating time, learn- ing curve issues, and lack of improvement in functional outcomes at mid-term follow-up.
Navigated TKA, due to its accuracy and low margins of error, has the potential to reduce component malalignment to within 1o to 2o of neutral mechanical axis.⁴ However, others have reported that alignment of the femoral and tibial components achieved with computer navigation is not different than TKA using conventional techniques.^5-12 This lack of improvement reported in these studies may be due to a number of potential sources of errors, which can be either surgeon- or device-related. These errors may pre-dispose to discrepancies between alignments calculated by the computer and the actual position of the implants. Apart from software- and hardware-related calibration issues, the majority of inaccuracies, which are often surgeon-related, result from registration of anatomical landmarks, pin array movements after registration, incorrect bone cuts despite accurate jig placement, and incorrect placement of final components during cementation. Of these surgeon-related factors, variability in the identification of the anatomical landmarks appears to be critical and occurs due to anatomical variations or from inaccurate recognition of intraoperative bony landmarks. A recent study found that registration of the distal femoral epicondyles was more likely to be inaccurate than other anatomical landmarks, as it was found that a small change of 2 mm in the sagittal plane can lead to a 1o change in the femoral component rotation.¹³

Nevertheless, the general consensus from recent high- level evidence (Level I and II) suggests that navigated TKA leads to improved coronal-alignment outcomes and reduced numbers of outliers.^14-18 In a recent systematic review of 27 randomized controlled trials of 2541 patients, Hetaimish and colleagues19 compared the alignment outcomes of navigated with conventional TKA. The authors found that the navigated cohort had a significantly lower risk of producing a mechanical axis deviation of greater than 3o, compared with conventional TKA (relative risk [RR] = 0.37; P<.001). The femoral and tibial, coronal and sagittal malalignment (>3o) were also found to be significantly lower with navigated TKA, compared with conventional techniques. However, no substantial differences were found in the rotation alignment of the femoral component between the 2 comparison cohorts (navigated group, 18.8%; conventional group, 14.5%).

Advocates of navigation believe that improved component alignment would lead to better functional outcomes and lower revision rates.^20,21 However, at short- to mid-term follow-up, most studies have failed to show any substantial benefits in terms of functional outcomes, revision rates, patient satisfaction, or patient-perceived quality-of-life, when comparing computer-assisted navigation to conventional techniques.^11,22-25 Recent systematic reviews by Zamora et al²⁴ and Burnett et al25 found no significant differences in the functional outcomes between navigated and conventional TKA (P>.05). This lack of the expected improvement in functional outcomes reported in various studies with navigation could be due to variability in registration of anatomical landmarks leading to errors in the rotational axis, or a lack of complete understanding of the interplay of alignment, ligament balance, in vivo joint loading and kinematics. In a report from the Mayo Clinic,²⁶ the authors believed that there may be little practical value in relying on a mechanical alignment of ±3o from neutral as an isolated variable in predicting the longevity of modern TKA. In addition, they suggested that factors apart from mechanical alignment may have a more profound impact on implant durability.

Several studies^27-31 that compared the joint line changes or ligament balance between navigated and conventional TKA, report no substantial differences in the maintenance of the joint line, quality of life, and functional outcomes. Despite claims of decreased blood loss, length-of stay, cardiac complications, and lower risks of fat embolism with computer-assisted navigation by some authors, other reports have failed to demonstrate any substantial advantages, therefore, it is controversial if any clear benefit exists.^6,32-34 It is postulated that the high initial institutional costs of navigation can even out in the long run if the goals of improved survivorship and functional outcomes are achieved.³⁵ However, as mid-term follow-up studies have failed to show a survival or functional benefit, the purported costs savings from computer navigation may not be accurate. Navigated TKA has been reported to increase operative time by about 15 to 20 minutes, compared with conventional TKA. Although, this increases operative time, it has not been reported to increase the risk of deep prosthetic joint infections.

Navigation provides some benefits in terms of radiological alignment. However, the clinical advantages are yet to be defined. Currently, there are many unanswered ques- tions concerning alignment in TKA, such as having a more individual approach based on the patients’ own anatomic variations including considerations about the presence of constitutional varus in patients. Navigation may have a role when TKA is performed for complex deformities, fractures, or in the presence of retained implants that prevent the use of conventional guides. Nevertheless, one should always keep in mind cost considerations. This has been true with any technological advancement we have had in the past and will be of concern in the future as well, especially with rising healthcare costs. When analyzing costs with naviga- tion, one must take in to account not only the overall costs of technology, but also the added costs of training, increased operating room times, and disposables when performing these procedures. Although we are advocates of change and are excited about this technology, the cost-benefit ratio for computer navigated TKA needs to be reconciled.

Although many physicians would like to "prescribe" health apps to their patients, it can be a daunting endeavor. The exact number of medical and wellness apps currently available is unknown – I’ve seen numbers range from 40,000 to 97,000. Even the most astute physician will have difficulty navigating this ocean of options.

Fortunately, there are sites that do the legwork for us, including wellocracy.com, imedicalapps.com, medicalappjournal.com, medgadget.com, and mashable.com.

The Food and Drug Administration divides health apps into two categories: medical apps and health and wellness apps. Medical apps are those that turn your mobile device into a medical device; for example, allowing users to take a picture of a mole or to record their blood pressure and send it to their physician. By contrast, health and wellness apps help patients maintain healthy lifestyles and often employ self-tracking, such as tracking activity levels and calories consumed. The most popular of this latter type include weight loss and fitness apps.

As health care providers, we have a responsibility to encourage our patients to be actively engaged in their health. Recommending health and wellness apps that help patients track their activity can be powerful tools for patient engagement since tracking allows users see data that inspire them to set and reach goals.

Below are seven health and wellness apps that earn top scores from users and reviewers alike:

• WebMD: WebMD’s app receives high ratings for its simple, clean interface. Users choose among "lifestyle topics" that interest them, such as "fitness and exercise" or "parenting and family." Other key features include a symptom checker; first-aid tips; a list of local doctors, hospitals, and pharmacies; and a pill ID feature that lets users identify prescription drugs and OTC meds by shape, color, and imprint. Cost: Free.

• MyFitnessPal: This app consistently receives high scores from users striving to lose weight. With scores of cardio and strength training exercises and more than 2 million food entries including restaurant meals and packaged foods in its database, it makes both tracking one’s daily activity and calorie counting simple. Cost: Free.

• Fitocracy: What makes this fitness app so wildly popular among users? Its social gaming component. Not only do users track their activity levels, but they also connect with and compete against others. Similar to a video game, users earn points and badges that help them "level up" and reinforce their adherence to a healthy lifestyle. Cost: Free.

• MyQuit Coach: Consistently ranked one the top quit smoking apps, MyQuitCoach personalizes strategies to help users kick the habit. Users can commit to either quitting immediately or reducing smoking over time. Cost: Free.

• Sleep Cycle: By providing easy-to-read graphs, this app helps analyze the user’s sleep patterns and wakes them up during the lightest sleep phase, the natural way to wake up. Cost: $1.99

• MediSafe:Physicians know firsthand the difficulty of getting patients to adhere to taking their prescription medications. This easy-to-use app helps by providing reminders to patients when they need to take their medication and by sharing information with a "Med-Friend," which can be a family member or caretaker. The app also alerts users when it’s time for a refill. Cost: Free

• iTriage: This app uses location-based technology to help users find the nearest hospital or urgent care center. It is ideal for travelers, as well as people new to a neighborhood. Perhaps its best feature is its ability to provide an estimated wait time. Cost: Free

Wellness apps do not provide cures for illnesses, but they can help patients improve their overall health by encouraging them to make smarter, healthier lifestyle choices. And that’s something any physician can support.

Dr. Jeffrey Benabio is a practicing dermatologist and physician director of healthcare transformation at Kaiser Permanente in San Diego. Connect with him on Twitter @Dermdoc or drop him a line at [email protected].

Although many physicians would like to "prescribe" health apps to their patients, it can be a daunting endeavor. The exact number of medical and wellness apps currently available is unknown – I’ve seen numbers range from 40,000 to 97,000. Even the most astute physician will have difficulty navigating this ocean of options.

Fortunately, there are sites that do the legwork for us, including wellocracy.com, imedicalapps.com, medicalappjournal.com, medgadget.com, and mashable.com.

The Food and Drug Administration divides health apps into two categories: medical apps and health and wellness apps. Medical apps are those that turn your mobile device into a medical device; for example, allowing users to take a picture of a mole or to record their blood pressure and send it to their physician. By contrast, health and wellness apps help patients maintain healthy lifestyles and often employ self-tracking, such as tracking activity levels and calories consumed. The most popular of this latter type include weight loss and fitness apps.

As health care providers, we have a responsibility to encourage our patients to be actively engaged in their health. Recommending health and wellness apps that help patients track their activity can be powerful tools for patient engagement since tracking allows users see data that inspire them to set and reach goals.

Below are seven health and wellness apps that earn top scores from users and reviewers alike:

• WebMD: WebMD’s app receives high ratings for its simple, clean interface. Users choose among "lifestyle topics" that interest them, such as "fitness and exercise" or "parenting and family." Other key features include a symptom checker; first-aid tips; a list of local doctors, hospitals, and pharmacies; and a pill ID feature that lets users identify prescription drugs and OTC meds by shape, color, and imprint. Cost: Free.

• MyFitnessPal: This app consistently receives high scores from users striving to lose weight. With scores of cardio and strength training exercises and more than 2 million food entries including restaurant meals and packaged foods in its database, it makes both tracking one’s daily activity and calorie counting simple. Cost: Free.

• Fitocracy: What makes this fitness app so wildly popular among users? Its social gaming component. Not only do users track their activity levels, but they also connect with and compete against others. Similar to a video game, users earn points and badges that help them "level up" and reinforce their adherence to a healthy lifestyle. Cost: Free.

• MyQuit Coach: Consistently ranked one the top quit smoking apps, MyQuitCoach personalizes strategies to help users kick the habit. Users can commit to either quitting immediately or reducing smoking over time. Cost: Free.

• Sleep Cycle: By providing easy-to-read graphs, this app helps analyze the user’s sleep patterns and wakes them up during the lightest sleep phase, the natural way to wake up. Cost: $1.99

• MediSafe:Physicians know firsthand the difficulty of getting patients to adhere to taking their prescription medications. This easy-to-use app helps by providing reminders to patients when they need to take their medication and by sharing information with a "Med-Friend," which can be a family member or caretaker. The app also alerts users when it’s time for a refill. Cost: Free

• iTriage: This app uses location-based technology to help users find the nearest hospital or urgent care center. It is ideal for travelers, as well as people new to a neighborhood. Perhaps its best feature is its ability to provide an estimated wait time. Cost: Free

Wellness apps do not provide cures for illnesses, but they can help patients improve their overall health by encouraging them to make smarter, healthier lifestyle choices. And that’s something any physician can support.

Dr. Jeffrey Benabio is a practicing dermatologist and physician director of healthcare transformation at Kaiser Permanente in San Diego. Connect with him on Twitter @Dermdoc or drop him a line at [email protected].

Although many physicians would like to "prescribe" health apps to their patients, it can be a daunting endeavor. The exact number of medical and wellness apps currently available is unknown – I’ve seen numbers range from 40,000 to 97,000. Even the most astute physician will have difficulty navigating this ocean of options.

Fortunately, there are sites that do the legwork for us, including wellocracy.com, imedicalapps.com, medicalappjournal.com, medgadget.com, and mashable.com.

The Food and Drug Administration divides health apps into two categories: medical apps and health and wellness apps. Medical apps are those that turn your mobile device into a medical device; for example, allowing users to take a picture of a mole or to record their blood pressure and send it to their physician. By contrast, health and wellness apps help patients maintain healthy lifestyles and often employ self-tracking, such as tracking activity levels and calories consumed. The most popular of this latter type include weight loss and fitness apps.

As health care providers, we have a responsibility to encourage our patients to be actively engaged in their health. Recommending health and wellness apps that help patients track their activity can be powerful tools for patient engagement since tracking allows users see data that inspire them to set and reach goals.

Below are seven health and wellness apps that earn top scores from users and reviewers alike:

• WebMD: WebMD’s app receives high ratings for its simple, clean interface. Users choose among "lifestyle topics" that interest them, such as "fitness and exercise" or "parenting and family." Other key features include a symptom checker; first-aid tips; a list of local doctors, hospitals, and pharmacies; and a pill ID feature that lets users identify prescription drugs and OTC meds by shape, color, and imprint. Cost: Free.

• MyFitnessPal: This app consistently receives high scores from users striving to lose weight. With scores of cardio and strength training exercises and more than 2 million food entries including restaurant meals and packaged foods in its database, it makes both tracking one’s daily activity and calorie counting simple. Cost: Free.

• Fitocracy: What makes this fitness app so wildly popular among users? Its social gaming component. Not only do users track their activity levels, but they also connect with and compete against others. Similar to a video game, users earn points and badges that help them "level up" and reinforce their adherence to a healthy lifestyle. Cost: Free.

• MyQuit Coach: Consistently ranked one the top quit smoking apps, MyQuitCoach personalizes strategies to help users kick the habit. Users can commit to either quitting immediately or reducing smoking over time. Cost: Free.

• Sleep Cycle: By providing easy-to-read graphs, this app helps analyze the user’s sleep patterns and wakes them up during the lightest sleep phase, the natural way to wake up. Cost: $1.99

• MediSafe:Physicians know firsthand the difficulty of getting patients to adhere to taking their prescription medications. This easy-to-use app helps by providing reminders to patients when they need to take their medication and by sharing information with a "Med-Friend," which can be a family member or caretaker. The app also alerts users when it’s time for a refill. Cost: Free

• iTriage: This app uses location-based technology to help users find the nearest hospital or urgent care center. It is ideal for travelers, as well as people new to a neighborhood. Perhaps its best feature is its ability to provide an estimated wait time. Cost: Free

Wellness apps do not provide cures for illnesses, but they can help patients improve their overall health by encouraging them to make smarter, healthier lifestyle choices. And that’s something any physician can support.

Dr. Jeffrey Benabio is a practicing dermatologist and physician director of healthcare transformation at Kaiser Permanente in San Diego. Connect with him on Twitter @Dermdoc or drop him a line at [email protected].

Mentha piperita, better known as peppermint, is used worldwide in many ways. Its use for culinary and medical purposes dates back to the ancient Greek and Roman civilizations. Peppermint is used in numerous forms (i.e., oil, leaf, leaf extract, and leaf water), with the oil as the most versatile (Dermatitis 2010;21:327-9). Peppermint has long been known for its beneficial gastrointestinal effects, and it has a well-established record of antimicrobial, antifungal, and analgesic activity (Mills S., Bone K. Principles and Practice of Phytotherapy: Modern Herbal Medicine. [London: Churchill Livingstone, 2000, pp 507-13]; J. Environ. Biol. 2011;32:23-9).

Courtesy Wikimedia Commons/Vsolymossy/Creative Commons License

Menthol (C10H20O) is a naturally occurring monocyclic terpene alcohol derived from Mentha piperita as well as other mint oils (Skin Therapy Lett. 2010;15:5-9), and has been associated with several health benefits. Recently, anticancer properties have been ascribed to menthol (Biochim. Biophys. Acta 2009;1792:33-8). This column will discuss recent findings regarding the actual or potential cutaneous benefits of peppermint and menthol.

Various Mentha species, including M. piperita, have exhibited significant antioxidant activity (Toxicol. Ind. Health. 2012;28:83-9; Nat. Prod. Commun. 2009;4:1107-12; Nat. Prod. Commun. 2009;4:535-42). In a 2010 study of the antioxidant activity of the essential oils of six popular herbs, including lavender (Lavendular angustifolia), peppermint (M. piperita), rosemary (Rosmarius officinalis), lemon (Citrus limon), grapefruit (C. paradise), and frankincense (Boswellia carteri), investigators found, in testing free radical-scavenging capacity and lipid peroxidation in the linoleic acid system, that peppermint essential oil exhibited the greatest radical-scavenging activity against the 2,2\'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) ABTS radical (Nat. Prod. Res. 2010;24:140-51).

In 2010, Baliga and Rao showed that M. piperita and M. arvensis (wild mint) protected mice against gamma-radiation–induced morbidity and mortality. Specifically, M. piperita protected murine testes as well as gastrointestinal and hemopoietic systems (J. Cancer Res. Ther. 2010;6:255-62).

Anticancer activity

Investigations by Jain et al. into the molecular mechanisms supporting the anticarcinogenic potential of M. piperita leaf extracts on six human cancer cell lines (HeLa, MCF-7, Jurkat, T24, HT-29, MIAPaCa-2) in 2011 revealed that chloroform and ethyl acetate extracts dose- and time-dependently displayed anticarcinogenic activity leading to G1 cell cycle arrest and mitochondrial-mediated apoptosis among the cascade of effects. The investigators identified their findings as the first evidence of direct anticarcinogenic activity of Mentha leaf extracts and suggested that future work might focus on isolating active constituents as a foundation for mechanistic and translational studies leading to new anticancer drugs, alone or in combination, to prevent and treat human cancers (Int. J. Toxicol. 2011;30:225-36).

Topical benefits of menthol

In a recent examination of the antibacterial and antifungal properties, as well as speculated anti-inflammatory activity of menthol as a topical treatment for diaper dermatitis, investigators conducted a pilot clinical trial in a hospital setting. The study involved 84 neonates with diagnosed candidal diaper dermatitis who required no critical care or systemic antifungal and anti-inflammatory medications. The menthol group (n = 42) received topical clotrimazole and topically applied menthol drops and the control group (n = 42) received topical clotrimazole and a placebo. Thirty-five infants in each group completed the study. The researchers found that complete healing was shorter in the menthol group, with significant relief of erythema and pustules observed in this group. They concluded that topically-applied menthol may be an effective agent in the treatment of candidal diaper dermatitis (World J. Pediatr. 2011;7:167-70).

In 2011, Qiu et al. showed, through various assays, that menthol, in low concentrations, could significantly suppress the expression of alpha-hemolysin, enterotoxins A and B, and toxic shock syndrome toxin 1 in Staphylococcus aureus. The investigators concluded that menthol may warrant inclusion in the armamentarium against S. aureus when combined with beta-lactam antibiotics, which, at subinhibitory concentrations, can actually augment S. aureus toxin secretion. They added that menthol may also have possible uses in novel anti-virulence drugs (Appl. Microbiol. Biotechnol. 2011;90:705-12). It should be noted that menthol is considered safe and effective, with concentrations up to 16% approved in OTC external products by the Food and Drug Administration (J. Am. Acad. Dermatol. 2007;57:873-8).

Pruritus, TRPM8, and melanoma

Topically applied menthol, in concentrations of 1%-3%, is often used to treat pruritus, particularly in the elderly (Skin Therapy Lett. 2010;15:5-9). In addition, recent evidence suggests that the presence of menthol can facilitate penetration of other agents in topical products (Int. J. Toxicol. 2001;20 Suppl 3:61-73; J. Am. Acad. Dermatol. 2007;57:873-8). Patel and Yosipovitch suggest that elderly patients who report diminished pruritus with cooling may stand to benefit from menthol-containing topical therapies (J. Am. Acad. Dermatol. 2007;57:873-8; Skin Therapy Lett. 2010;15:5-9). Interestingly, menthol, via the transient receptor potential melastatin subfamily 8 (TRPM8) receptor, a member of a family of excitatory ion channels, engenders the same cooling sensation as low temperature, though menthol is not linked to a reduction in skin temperature (J. Am. Acad. Dermatol. 2007;57:873-8; Skin Therapy Lett. 2010;15:5-9).

Although the exact mechanism by which menthol exerts its antipruritic and analgesic effects has yet to be determined, the discovery that the TRPM8 is its underlying receptor is proving to be significant, particularly in understanding the cooling effect of the botanical (J. Am. Acad. Dermatol. 2007;57:873-8). There are also indications that menthol has therapeutic potential for melanoma. Specifically, melanoma expresses TRPM8 receptors, the activation of which inhibits melanoma viability. Menthol appears to mediate this response through an influx of extracellular calcium ions (Am. J. Physiol. Cell Physiol. 2008;295:C296-301; Am. J. Physiol. Cell Physiol. 2008;295:C293-5).

Peppermint oil

In 2003, Schuhmacher et al. investigated the virucidal effect of peppermint oil and found that it had a direct effect against herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) as well as an acyclovir-resistant HSV-1 strain. The investigators concluded, noting the lipophilic nature of peppermint oil, that it might be an appropriate topical treatment for recurrent herpes outbreaks (Phytomedicine 2003;10:504-10).

Because of its flavor, aroma, and cooling qualities, peppermint oil is used in a wide range of products, including cosmeceuticals, personal hygiene products (e.g., bath preparations, mouthwashes, toothpastes, and topical formulations), foods, pharmaceutical products, and aromatherapy. Topical indications include pruritus, irritation, and inflammation. Peppermint oil can act as a skin sensitizer, though, particularly in impaired and sensitive skin (Dermatitis 2010;21:327-9). Although peppermint oil has been reported to be a sensitizer in isolated cases, peppermint oil 8% was not found to be a sensitizer in a recent test using a maximization protocol and the various forms of peppermint (i.e., oil, extract, leaves, and water) are considered to be safe in cosmetic formulations. In rinse-off products, peppermint oil is used in concentrations up to 3% and up to 0.2% in leave-on formulations (Int. J. Toxicol. 2001;20 Suppl 3:61-73).

Conclusion

Peppermint and menthol, its naturally occurring monocyclic terpene alcohol derivative, have long been used for medical purposes. Contemporary practice and continuing research continue to support various uses of M. piperita in the medical armamentarium, with specific and additional uses continually being found in the dermatologic realm.

Dr. Baumann is chief executive officer of the Baumann Cosmetic & Research Institute in Miami Beach. She founded the cosmetic dermatology center at the University of Miami in 1997. Dr. Baumann wrote the textbook "Cosmetic Dermatology: Principles and Practice" (McGraw-Hill, April 2002), and a book for consumers, "The Skin Type Solution" (Bantam, 2006). She has contributed to the Cosmeceutical Critique column in Skin & Allergy News since January 2001 and joined the editorial advisory board in 2004. Dr. Baumann has received funding for clinical grants from Allergan, Aveeno, Avon Products, Galderma, Mary Kay, Medicis Pharmaceuticals, Neutrogena, Philosophy, Stiefel, Topix Pharmaceuticals, and Unilever.

Mentha piperita, better known as peppermint, is used worldwide in many ways. Its use for culinary and medical purposes dates back to the ancient Greek and Roman civilizations. Peppermint is used in numerous forms (i.e., oil, leaf, leaf extract, and leaf water), with the oil as the most versatile (Dermatitis 2010;21:327-9). Peppermint has long been known for its beneficial gastrointestinal effects, and it has a well-established record of antimicrobial, antifungal, and analgesic activity (Mills S., Bone K. Principles and Practice of Phytotherapy: Modern Herbal Medicine. [London: Churchill Livingstone, 2000, pp 507-13]; J. Environ. Biol. 2011;32:23-9).

Courtesy Wikimedia Commons/Vsolymossy/Creative Commons License

Menthol (C10H20O) is a naturally occurring monocyclic terpene alcohol derived from Mentha piperita as well as other mint oils (Skin Therapy Lett. 2010;15:5-9), and has been associated with several health benefits. Recently, anticancer properties have been ascribed to menthol (Biochim. Biophys. Acta 2009;1792:33-8). This column will discuss recent findings regarding the actual or potential cutaneous benefits of peppermint and menthol.

Various Mentha species, including M. piperita, have exhibited significant antioxidant activity (Toxicol. Ind. Health. 2012;28:83-9; Nat. Prod. Commun. 2009;4:1107-12; Nat. Prod. Commun. 2009;4:535-42). In a 2010 study of the antioxidant activity of the essential oils of six popular herbs, including lavender (Lavendular angustifolia), peppermint (M. piperita), rosemary (Rosmarius officinalis), lemon (Citrus limon), grapefruit (C. paradise), and frankincense (Boswellia carteri), investigators found, in testing free radical-scavenging capacity and lipid peroxidation in the linoleic acid system, that peppermint essential oil exhibited the greatest radical-scavenging activity against the 2,2\'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) ABTS radical (Nat. Prod. Res. 2010;24:140-51).

In 2010, Baliga and Rao showed that M. piperita and M. arvensis (wild mint) protected mice against gamma-radiation–induced morbidity and mortality. Specifically, M. piperita protected murine testes as well as gastrointestinal and hemopoietic systems (J. Cancer Res. Ther. 2010;6:255-62).

Anticancer activity

Investigations by Jain et al. into the molecular mechanisms supporting the anticarcinogenic potential of M. piperita leaf extracts on six human cancer cell lines (HeLa, MCF-7, Jurkat, T24, HT-29, MIAPaCa-2) in 2011 revealed that chloroform and ethyl acetate extracts dose- and time-dependently displayed anticarcinogenic activity leading to G1 cell cycle arrest and mitochondrial-mediated apoptosis among the cascade of effects. The investigators identified their findings as the first evidence of direct anticarcinogenic activity of Mentha leaf extracts and suggested that future work might focus on isolating active constituents as a foundation for mechanistic and translational studies leading to new anticancer drugs, alone or in combination, to prevent and treat human cancers (Int. J. Toxicol. 2011;30:225-36).

Topical benefits of menthol

In a recent examination of the antibacterial and antifungal properties, as well as speculated anti-inflammatory activity of menthol as a topical treatment for diaper dermatitis, investigators conducted a pilot clinical trial in a hospital setting. The study involved 84 neonates with diagnosed candidal diaper dermatitis who required no critical care or systemic antifungal and anti-inflammatory medications. The menthol group (n = 42) received topical clotrimazole and topically applied menthol drops and the control group (n = 42) received topical clotrimazole and a placebo. Thirty-five infants in each group completed the study. The researchers found that complete healing was shorter in the menthol group, with significant relief of erythema and pustules observed in this group. They concluded that topically-applied menthol may be an effective agent in the treatment of candidal diaper dermatitis (World J. Pediatr. 2011;7:167-70).

In 2011, Qiu et al. showed, through various assays, that menthol, in low concentrations, could significantly suppress the expression of alpha-hemolysin, enterotoxins A and B, and toxic shock syndrome toxin 1 in Staphylococcus aureus. The investigators concluded that menthol may warrant inclusion in the armamentarium against S. aureus when combined with beta-lactam antibiotics, which, at subinhibitory concentrations, can actually augment S. aureus toxin secretion. They added that menthol may also have possible uses in novel anti-virulence drugs (Appl. Microbiol. Biotechnol. 2011;90:705-12). It should be noted that menthol is considered safe and effective, with concentrations up to 16% approved in OTC external products by the Food and Drug Administration (J. Am. Acad. Dermatol. 2007;57:873-8).

Pruritus, TRPM8, and melanoma

Topically applied menthol, in concentrations of 1%-3%, is often used to treat pruritus, particularly in the elderly (Skin Therapy Lett. 2010;15:5-9). In addition, recent evidence suggests that the presence of menthol can facilitate penetration of other agents in topical products (Int. J. Toxicol. 2001;20 Suppl 3:61-73; J. Am. Acad. Dermatol. 2007;57:873-8). Patel and Yosipovitch suggest that elderly patients who report diminished pruritus with cooling may stand to benefit from menthol-containing topical therapies (J. Am. Acad. Dermatol. 2007;57:873-8; Skin Therapy Lett. 2010;15:5-9). Interestingly, menthol, via the transient receptor potential melastatin subfamily 8 (TRPM8) receptor, a member of a family of excitatory ion channels, engenders the same cooling sensation as low temperature, though menthol is not linked to a reduction in skin temperature (J. Am. Acad. Dermatol. 2007;57:873-8; Skin Therapy Lett. 2010;15:5-9).

Although the exact mechanism by which menthol exerts its antipruritic and analgesic effects has yet to be determined, the discovery that the TRPM8 is its underlying receptor is proving to be significant, particularly in understanding the cooling effect of the botanical (J. Am. Acad. Dermatol. 2007;57:873-8). There are also indications that menthol has therapeutic potential for melanoma. Specifically, melanoma expresses TRPM8 receptors, the activation of which inhibits melanoma viability. Menthol appears to mediate this response through an influx of extracellular calcium ions (Am. J. Physiol. Cell Physiol. 2008;295:C296-301; Am. J. Physiol. Cell Physiol. 2008;295:C293-5).

Peppermint oil

In 2003, Schuhmacher et al. investigated the virucidal effect of peppermint oil and found that it had a direct effect against herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) as well as an acyclovir-resistant HSV-1 strain. The investigators concluded, noting the lipophilic nature of peppermint oil, that it might be an appropriate topical treatment for recurrent herpes outbreaks (Phytomedicine 2003;10:504-10).

Because of its flavor, aroma, and cooling qualities, peppermint oil is used in a wide range of products, including cosmeceuticals, personal hygiene products (e.g., bath preparations, mouthwashes, toothpastes, and topical formulations), foods, pharmaceutical products, and aromatherapy. Topical indications include pruritus, irritation, and inflammation. Peppermint oil can act as a skin sensitizer, though, particularly in impaired and sensitive skin (Dermatitis 2010;21:327-9). Although peppermint oil has been reported to be a sensitizer in isolated cases, peppermint oil 8% was not found to be a sensitizer in a recent test using a maximization protocol and the various forms of peppermint (i.e., oil, extract, leaves, and water) are considered to be safe in cosmetic formulations. In rinse-off products, peppermint oil is used in concentrations up to 3% and up to 0.2% in leave-on formulations (Int. J. Toxicol. 2001;20 Suppl 3:61-73).

Conclusion

Peppermint and menthol, its naturally occurring monocyclic terpene alcohol derivative, have long been used for medical purposes. Contemporary practice and continuing research continue to support various uses of M. piperita in the medical armamentarium, with specific and additional uses continually being found in the dermatologic realm.

Dr. Baumann is chief executive officer of the Baumann Cosmetic & Research Institute in Miami Beach. She founded the cosmetic dermatology center at the University of Miami in 1997. Dr. Baumann wrote the textbook "Cosmetic Dermatology: Principles and Practice" (McGraw-Hill, April 2002), and a book for consumers, "The Skin Type Solution" (Bantam, 2006). She has contributed to the Cosmeceutical Critique column in Skin & Allergy News since January 2001 and joined the editorial advisory board in 2004. Dr. Baumann has received funding for clinical grants from Allergan, Aveeno, Avon Products, Galderma, Mary Kay, Medicis Pharmaceuticals, Neutrogena, Philosophy, Stiefel, Topix Pharmaceuticals, and Unilever.

Mentha piperita, better known as peppermint, is used worldwide in many ways. Its use for culinary and medical purposes dates back to the ancient Greek and Roman civilizations. Peppermint is used in numerous forms (i.e., oil, leaf, leaf extract, and leaf water), with the oil as the most versatile (Dermatitis 2010;21:327-9). Peppermint has long been known for its beneficial gastrointestinal effects, and it has a well-established record of antimicrobial, antifungal, and analgesic activity (Mills S., Bone K. Principles and Practice of Phytotherapy: Modern Herbal Medicine. [London: Churchill Livingstone, 2000, pp 507-13]; J. Environ. Biol. 2011;32:23-9).

Courtesy Wikimedia Commons/Vsolymossy/Creative Commons License

Menthol (C10H20O) is a naturally occurring monocyclic terpene alcohol derived from Mentha piperita as well as other mint oils (Skin Therapy Lett. 2010;15:5-9), and has been associated with several health benefits. Recently, anticancer properties have been ascribed to menthol (Biochim. Biophys. Acta 2009;1792:33-8). This column will discuss recent findings regarding the actual or potential cutaneous benefits of peppermint and menthol.

Various Mentha species, including M. piperita, have exhibited significant antioxidant activity (Toxicol. Ind. Health. 2012;28:83-9; Nat. Prod. Commun. 2009;4:1107-12; Nat. Prod. Commun. 2009;4:535-42). In a 2010 study of the antioxidant activity of the essential oils of six popular herbs, including lavender (Lavendular angustifolia), peppermint (M. piperita), rosemary (Rosmarius officinalis), lemon (Citrus limon), grapefruit (C. paradise), and frankincense (Boswellia carteri), investigators found, in testing free radical-scavenging capacity and lipid peroxidation in the linoleic acid system, that peppermint essential oil exhibited the greatest radical-scavenging activity against the 2,2\'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) ABTS radical (Nat. Prod. Res. 2010;24:140-51).

In 2010, Baliga and Rao showed that M. piperita and M. arvensis (wild mint) protected mice against gamma-radiation–induced morbidity and mortality. Specifically, M. piperita protected murine testes as well as gastrointestinal and hemopoietic systems (J. Cancer Res. Ther. 2010;6:255-62).

Anticancer activity

Investigations by Jain et al. into the molecular mechanisms supporting the anticarcinogenic potential of M. piperita leaf extracts on six human cancer cell lines (HeLa, MCF-7, Jurkat, T24, HT-29, MIAPaCa-2) in 2011 revealed that chloroform and ethyl acetate extracts dose- and time-dependently displayed anticarcinogenic activity leading to G1 cell cycle arrest and mitochondrial-mediated apoptosis among the cascade of effects. The investigators identified their findings as the first evidence of direct anticarcinogenic activity of Mentha leaf extracts and suggested that future work might focus on isolating active constituents as a foundation for mechanistic and translational studies leading to new anticancer drugs, alone or in combination, to prevent and treat human cancers (Int. J. Toxicol. 2011;30:225-36).

Topical benefits of menthol

In a recent examination of the antibacterial and antifungal properties, as well as speculated anti-inflammatory activity of menthol as a topical treatment for diaper dermatitis, investigators conducted a pilot clinical trial in a hospital setting. The study involved 84 neonates with diagnosed candidal diaper dermatitis who required no critical care or systemic antifungal and anti-inflammatory medications. The menthol group (n = 42) received topical clotrimazole and topically applied menthol drops and the control group (n = 42) received topical clotrimazole and a placebo. Thirty-five infants in each group completed the study. The researchers found that complete healing was shorter in the menthol group, with significant relief of erythema and pustules observed in this group. They concluded that topically-applied menthol may be an effective agent in the treatment of candidal diaper dermatitis (World J. Pediatr. 2011;7:167-70).

In 2011, Qiu et al. showed, through various assays, that menthol, in low concentrations, could significantly suppress the expression of alpha-hemolysin, enterotoxins A and B, and toxic shock syndrome toxin 1 in Staphylococcus aureus. The investigators concluded that menthol may warrant inclusion in the armamentarium against S. aureus when combined with beta-lactam antibiotics, which, at subinhibitory concentrations, can actually augment S. aureus toxin secretion. They added that menthol may also have possible uses in novel anti-virulence drugs (Appl. Microbiol. Biotechnol. 2011;90:705-12). It should be noted that menthol is considered safe and effective, with concentrations up to 16% approved in OTC external products by the Food and Drug Administration (J. Am. Acad. Dermatol. 2007;57:873-8).

Pruritus, TRPM8, and melanoma

Topically applied menthol, in concentrations of 1%-3%, is often used to treat pruritus, particularly in the elderly (Skin Therapy Lett. 2010;15:5-9). In addition, recent evidence suggests that the presence of menthol can facilitate penetration of other agents in topical products (Int. J. Toxicol. 2001;20 Suppl 3:61-73; J. Am. Acad. Dermatol. 2007;57:873-8). Patel and Yosipovitch suggest that elderly patients who report diminished pruritus with cooling may stand to benefit from menthol-containing topical therapies (J. Am. Acad. Dermatol. 2007;57:873-8; Skin Therapy Lett. 2010;15:5-9). Interestingly, menthol, via the transient receptor potential melastatin subfamily 8 (TRPM8) receptor, a member of a family of excitatory ion channels, engenders the same cooling sensation as low temperature, though menthol is not linked to a reduction in skin temperature (J. Am. Acad. Dermatol. 2007;57:873-8; Skin Therapy Lett. 2010;15:5-9).

Although the exact mechanism by which menthol exerts its antipruritic and analgesic effects has yet to be determined, the discovery that the TRPM8 is its underlying receptor is proving to be significant, particularly in understanding the cooling effect of the botanical (J. Am. Acad. Dermatol. 2007;57:873-8). There are also indications that menthol has therapeutic potential for melanoma. Specifically, melanoma expresses TRPM8 receptors, the activation of which inhibits melanoma viability. Menthol appears to mediate this response through an influx of extracellular calcium ions (Am. J. Physiol. Cell Physiol. 2008;295:C296-301; Am. J. Physiol. Cell Physiol. 2008;295:C293-5).

Peppermint oil

In 2003, Schuhmacher et al. investigated the virucidal effect of peppermint oil and found that it had a direct effect against herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) as well as an acyclovir-resistant HSV-1 strain. The investigators concluded, noting the lipophilic nature of peppermint oil, that it might be an appropriate topical treatment for recurrent herpes outbreaks (Phytomedicine 2003;10:504-10).

Because of its flavor, aroma, and cooling qualities, peppermint oil is used in a wide range of products, including cosmeceuticals, personal hygiene products (e.g., bath preparations, mouthwashes, toothpastes, and topical formulations), foods, pharmaceutical products, and aromatherapy. Topical indications include pruritus, irritation, and inflammation. Peppermint oil can act as a skin sensitizer, though, particularly in impaired and sensitive skin (Dermatitis 2010;21:327-9). Although peppermint oil has been reported to be a sensitizer in isolated cases, peppermint oil 8% was not found to be a sensitizer in a recent test using a maximization protocol and the various forms of peppermint (i.e., oil, extract, leaves, and water) are considered to be safe in cosmetic formulations. In rinse-off products, peppermint oil is used in concentrations up to 3% and up to 0.2% in leave-on formulations (Int. J. Toxicol. 2001;20 Suppl 3:61-73).

Conclusion

Peppermint and menthol, its naturally occurring monocyclic terpene alcohol derivative, have long been used for medical purposes. Contemporary practice and continuing research continue to support various uses of M. piperita in the medical armamentarium, with specific and additional uses continually being found in the dermatologic realm.

Dr. Baumann is chief executive officer of the Baumann Cosmetic & Research Institute in Miami Beach. She founded the cosmetic dermatology center at the University of Miami in 1997. Dr. Baumann wrote the textbook "Cosmetic Dermatology: Principles and Practice" (McGraw-Hill, April 2002), and a book for consumers, "The Skin Type Solution" (Bantam, 2006). She has contributed to the Cosmeceutical Critique column in Skin & Allergy News since January 2001 and joined the editorial advisory board in 2004. Dr. Baumann has received funding for clinical grants from Allergan, Aveeno, Avon Products, Galderma, Mary Kay, Medicis Pharmaceuticals, Neutrogena, Philosophy, Stiefel, Topix Pharmaceuticals, and Unilever.

ISTANBUL – Both clinicians and patients gave favorable marks to a novel injectable pharmacologic treatment for removal of unwanted submental fat – the unsightly double chin – in two phase III randomized trials presented at the annual congress of the European Academy of Dermatology and Venereology.

The investigational chin-fat buster, known as ATX-101, is a proprietary purified synthetic form of deoxycholic acid. Upon injection directly into the submental fat, ATX-101 lyses adipocytes by disrupting their cell membranes.

There is an unmet need for a rigorously studied prescription product for nonsurgical treatment of excess submental fat. Not everyone with a double chin is interested in or a good candidate for the established surgical procedures, observed Dr. Berthold Rzany, a dermatologist at Charité University Hospital, Berlin, who presented a 363-patient, randomized, placebo-controlled phase III trial at the meeting. Participants had to have a body mass index no higher than 30 kg/m², dissatisfaction with the appearance of their submental area, and a physician rating of moderate to severe submental fat. Three-quarters of the subjects were women, with a mean age of 46 years and a mean BMI of 25.7 kg/m².

One of the two primary efficacy endpoints required at least a 1-point improvement on the 0- to 4-point Clinician-Reported Submental Fat Rating Scale as assessed 12 weeks after the final treatment. This was achieved in 59% of patients randomized to ATX-101 at a dose of 1mg/cm² and 65% at 2 mg/cm², both significantly higher rates than the 23% in placebo-treated controls.

The other primary endpoint required a high level of patient satisfaction with the appearance of their face and chin after treatment as expressed in a Subject Self-Rating Scale score of 4 or more on the 0-6 scale. This endpoint was achieved in 53% of patients treated with ATX-101 at 1 mg/cm², 66% who received the agent at 2 mg/cm², and 29% of the placebo group.

ATX-101-treated patients were also significantly more likely to report perceived improvement in the visual and psychological impact of their submental fat. For example, 74% of patients who received ATX-101 at 1 mg/cm² and 80% at 2 mg/cm² reported improved definition between their chin and neck, compared with baseline and compared with 28% of placebo-treated controls. In addition, 32% of patients who received the lower dose of ATX-101 and 39% who got the higher dose characterized their submental fat as "a great deal better," compared with baseline, as did a mere 7% of controls.

Also, patients who received ATX-101 reported 12 weeks post treatment that they looked less overweight and were less bothered by and self-conscious about their submental fat, compared with controls.

Treatment-emergent induration, redness, bruising, numbness, and/or swelling variously occurred in one-third to two-thirds of ATX-101 recipients. All of these adverse events were more common than in placebo-treated controls. However, the events were transient and mostly mild or moderate in intensity. The exception was injection site pain, which occurred in roughly 80% of ATX-101-treated patients and was mostly moderate to severe, although it lasted a median of only 1 day, according to Dr. Rzany.

The ATX-101 treatment regimen entails up to 50 2-mL fixed-dose subcutaneous injections 1 cm apart per treatment session. Up to four treatment sessions were permitted, each separated by a minimum of 4 weeks.

In a separate presentation, Dr. Benjamin Ascher reported on 360 randomized patients who participated in the other phase III clinical trial. The two studies had the same design and endpoints.

An improvement of at least 1 point on the Clinician-Reported Submental Fat Rating Scale occurred in 58% of patients randomized to ATX-101 at the 1 mg/cm² dose, 62% of those who received the higher dose, and 35% on placebo. Moreover, 68% of patients who got ATX-101 at 1 mg/cm² were satisfied with their resultant appearance as reflected in a Subject Self-Rating Scale score of at least 4. So were 65% of those who received the higher dose and 29% of placebo-treated controls. As in the previously mentioned study, indices of self-image and psychological well being were also improved following the aesthetic therapy. Treatment-related adverse events were mostly transient and mild to moderate in intensity, according to Dr. Ascher, who is in the private practice of aesthetic surgery in Paris.

Both phase III studies were supported by Bayer HealthCare and KYTHERA Biopharmaceuticals. Dr. Rzany and Dr. Ascher serve as advisers to the companies.

[email protected]

ISTANBUL – Both clinicians and patients gave favorable marks to a novel injectable pharmacologic treatment for removal of unwanted submental fat – the unsightly double chin – in two phase III randomized trials presented at the annual congress of the European Academy of Dermatology and Venereology.

The investigational chin-fat buster, known as ATX-101, is a proprietary purified synthetic form of deoxycholic acid. Upon injection directly into the submental fat, ATX-101 lyses adipocytes by disrupting their cell membranes.

There is an unmet need for a rigorously studied prescription product for nonsurgical treatment of excess submental fat. Not everyone with a double chin is interested in or a good candidate for the established surgical procedures, observed Dr. Berthold Rzany, a dermatologist at Charité University Hospital, Berlin, who presented a 363-patient, randomized, placebo-controlled phase III trial at the meeting. Participants had to have a body mass index no higher than 30 kg/m², dissatisfaction with the appearance of their submental area, and a physician rating of moderate to severe submental fat. Three-quarters of the subjects were women, with a mean age of 46 years and a mean BMI of 25.7 kg/m².

One of the two primary efficacy endpoints required at least a 1-point improvement on the 0- to 4-point Clinician-Reported Submental Fat Rating Scale as assessed 12 weeks after the final treatment. This was achieved in 59% of patients randomized to ATX-101 at a dose of 1mg/cm² and 65% at 2 mg/cm², both significantly higher rates than the 23% in placebo-treated controls.

The other primary endpoint required a high level of patient satisfaction with the appearance of their face and chin after treatment as expressed in a Subject Self-Rating Scale score of 4 or more on the 0-6 scale. This endpoint was achieved in 53% of patients treated with ATX-101 at 1 mg/cm², 66% who received the agent at 2 mg/cm², and 29% of the placebo group.

ATX-101-treated patients were also significantly more likely to report perceived improvement in the visual and psychological impact of their submental fat. For example, 74% of patients who received ATX-101 at 1 mg/cm² and 80% at 2 mg/cm² reported improved definition between their chin and neck, compared with baseline and compared with 28% of placebo-treated controls. In addition, 32% of patients who received the lower dose of ATX-101 and 39% who got the higher dose characterized their submental fat as "a great deal better," compared with baseline, as did a mere 7% of controls.

Also, patients who received ATX-101 reported 12 weeks post treatment that they looked less overweight and were less bothered by and self-conscious about their submental fat, compared with controls.

Treatment-emergent induration, redness, bruising, numbness, and/or swelling variously occurred in one-third to two-thirds of ATX-101 recipients. All of these adverse events were more common than in placebo-treated controls. However, the events were transient and mostly mild or moderate in intensity. The exception was injection site pain, which occurred in roughly 80% of ATX-101-treated patients and was mostly moderate to severe, although it lasted a median of only 1 day, according to Dr. Rzany.

The ATX-101 treatment regimen entails up to 50 2-mL fixed-dose subcutaneous injections 1 cm apart per treatment session. Up to four treatment sessions were permitted, each separated by a minimum of 4 weeks.

In a separate presentation, Dr. Benjamin Ascher reported on 360 randomized patients who participated in the other phase III clinical trial. The two studies had the same design and endpoints.

An improvement of at least 1 point on the Clinician-Reported Submental Fat Rating Scale occurred in 58% of patients randomized to ATX-101 at the 1 mg/cm² dose, 62% of those who received the higher dose, and 35% on placebo. Moreover, 68% of patients who got ATX-101 at 1 mg/cm² were satisfied with their resultant appearance as reflected in a Subject Self-Rating Scale score of at least 4. So were 65% of those who received the higher dose and 29% of placebo-treated controls. As in the previously mentioned study, indices of self-image and psychological well being were also improved following the aesthetic therapy. Treatment-related adverse events were mostly transient and mild to moderate in intensity, according to Dr. Ascher, who is in the private practice of aesthetic surgery in Paris.

Both phase III studies were supported by Bayer HealthCare and KYTHERA Biopharmaceuticals. Dr. Rzany and Dr. Ascher serve as advisers to the companies.

[email protected]

ISTANBUL – Both clinicians and patients gave favorable marks to a novel injectable pharmacologic treatment for removal of unwanted submental fat – the unsightly double chin – in two phase III randomized trials presented at the annual congress of the European Academy of Dermatology and Venereology.

The investigational chin-fat buster, known as ATX-101, is a proprietary purified synthetic form of deoxycholic acid. Upon injection directly into the submental fat, ATX-101 lyses adipocytes by disrupting their cell membranes.

There is an unmet need for a rigorously studied prescription product for nonsurgical treatment of excess submental fat. Not everyone with a double chin is interested in or a good candidate for the established surgical procedures, observed Dr. Berthold Rzany, a dermatologist at Charité University Hospital, Berlin, who presented a 363-patient, randomized, placebo-controlled phase III trial at the meeting. Participants had to have a body mass index no higher than 30 kg/m², dissatisfaction with the appearance of their submental area, and a physician rating of moderate to severe submental fat. Three-quarters of the subjects were women, with a mean age of 46 years and a mean BMI of 25.7 kg/m².

One of the two primary efficacy endpoints required at least a 1-point improvement on the 0- to 4-point Clinician-Reported Submental Fat Rating Scale as assessed 12 weeks after the final treatment. This was achieved in 59% of patients randomized to ATX-101 at a dose of 1mg/cm² and 65% at 2 mg/cm², both significantly higher rates than the 23% in placebo-treated controls.

The other primary endpoint required a high level of patient satisfaction with the appearance of their face and chin after treatment as expressed in a Subject Self-Rating Scale score of 4 or more on the 0-6 scale. This endpoint was achieved in 53% of patients treated with ATX-101 at 1 mg/cm², 66% who received the agent at 2 mg/cm², and 29% of the placebo group.

ATX-101-treated patients were also significantly more likely to report perceived improvement in the visual and psychological impact of their submental fat. For example, 74% of patients who received ATX-101 at 1 mg/cm² and 80% at 2 mg/cm² reported improved definition between their chin and neck, compared with baseline and compared with 28% of placebo-treated controls. In addition, 32% of patients who received the lower dose of ATX-101 and 39% who got the higher dose characterized their submental fat as "a great deal better," compared with baseline, as did a mere 7% of controls.

Also, patients who received ATX-101 reported 12 weeks post treatment that they looked less overweight and were less bothered by and self-conscious about their submental fat, compared with controls.

Treatment-emergent induration, redness, bruising, numbness, and/or swelling variously occurred in one-third to two-thirds of ATX-101 recipients. All of these adverse events were more common than in placebo-treated controls. However, the events were transient and mostly mild or moderate in intensity. The exception was injection site pain, which occurred in roughly 80% of ATX-101-treated patients and was mostly moderate to severe, although it lasted a median of only 1 day, according to Dr. Rzany.

The ATX-101 treatment regimen entails up to 50 2-mL fixed-dose subcutaneous injections 1 cm apart per treatment session. Up to four treatment sessions were permitted, each separated by a minimum of 4 weeks.

In a separate presentation, Dr. Benjamin Ascher reported on 360 randomized patients who participated in the other phase III clinical trial. The two studies had the same design and endpoints.

An improvement of at least 1 point on the Clinician-Reported Submental Fat Rating Scale occurred in 58% of patients randomized to ATX-101 at the 1 mg/cm² dose, 62% of those who received the higher dose, and 35% on placebo. Moreover, 68% of patients who got ATX-101 at 1 mg/cm² were satisfied with their resultant appearance as reflected in a Subject Self-Rating Scale score of at least 4. So were 65% of those who received the higher dose and 29% of placebo-treated controls. As in the previously mentioned study, indices of self-image and psychological well being were also improved following the aesthetic therapy. Treatment-related adverse events were mostly transient and mild to moderate in intensity, according to Dr. Ascher, who is in the private practice of aesthetic surgery in Paris.

Both phase III studies were supported by Bayer HealthCare and KYTHERA Biopharmaceuticals. Dr. Rzany and Dr. Ascher serve as advisers to the companies.

[email protected]

As the date for implementing ICD-10 gets closer, consulting firms send daily offers to help us adapt to the new diagnostic regime. As a service to the profession, Under My Skin will provide periodic updates to save you consulting fees.

In an earlier column, you learned about new codes like injury from burning water skis. We also covered codes for envenomation by Gila monsters, both unintentional and intentional. You should know that these are already available under ICD-9. No need to wait till next year to use them!

ICD-9-CM E905.0: Venomous snakes and lizards causing poisoning and toxic reactions. These include the following: cobra, copperhead snake, coral snake, fer-de-lance snake, Gila monster, krait, mamba, viper, and several others. Do NOT use this code for bites by nonvenomous snakes and lizards. (That may come back to bite you ... Sorry!)

Anyone who can define a fer-de-lance or a krait is gets extra credit (but no extra payment). If you can either identify a mamba, or dance it, good for you!

ICD-10 naturally amplifies this inadequate taxonomy:

• T63.111 – Toxic effect of venom of Gila monster, accidental (unintentional)

• T63.112 – Toxic effect of venom of Gila monster, intentional (self-harm)

• T63.113 – Toxic effect of venom of Gila monster, assault

• T63.114 – Toxic effect of venom of Gila monster, undetermined

Questions: For the new "assault" code, was the Gila monster the assailant or was its owner? Does "undetermined" mean you don’t really know how you got bitten (come on, was that really an accident – weren’t you petting the Gila kind of roughly?) or that you didn’t determine whether it actually was a Gila monster (because it ran away so fast that that it could have been a marmoset).

There are other ICD-9 codes you can already use (right now!) I recently got a 6-page EMR from a referring clinic (you get those, don’t you?) listing one of the patient’s 14 diagnoses as E968.2: Assault by striking by blunt or thrown object.

This opened my eyes to:

• E968.5 – Assault by transport vehicle.

• E968.3 – Assault by hot liquid.

• E968.1 – Assault by pushing from a high place. (Questions: How high? How hot? Transporting what?)

While on the subject of injuries in high places, you might consider:

• E840.1 – Accident by powered aircraft at takeoff or landing.

Again, ICD-10 will be more comprehensive.

Looking at injury from burning water skis, we find:

• V91.07 – Burn due to water-skis on fire.

Within which are:

• V91.07XA ... initial encounter.

• V91.07XD ... subsequent encounter.

• V91.07XS ... sequela.

This is not all! V91.07 has many other subcategories:

• V91.0 – Burn due to watercraft on fire.

• V91.01 – Burn due to passenger ship on fire.

• V91.02 – Burn due to fishing boat on fire.

• V91.05 – Burn due to canoe or kayak on fire.

But wait! There is also V91.1 – Crushed between watercraft and other watercraft or other object due to collision. Within which are:

• V91.10 – Crushed between merchant ship and other watercraft or other object due to collision.

• V91.12 – Crushed between fishing boat and other watercraft or other object due to collision.

• V91.15 – Crushed between canoe or kayak and other watercraft or other object due to collision.

Each of these of course includes subcodes for: initial encounter, subsequent encounter, and sequela. (Conversion hysteria caused by paranoid fear of rampaging kayaks?)

The practical advantages to learning all this extend beyond the office. Suppose you’re fishing in a rowboat on a lazy Sunday afternoon when a kayaker waving a flaming blowtorch careens toward you full tilt and you leap overboard. When the Coast Guard pulls you out, you can shout, "V91.05! V91.15!"

In our next installment, we will take up other subsets of external causes of morbidity, including:

• W20 – struck by thrown, projected, or falling object such as:

• W20.0 – Falling object in cave (initial encounter, subsequent encounter, sequela).

• W20.1 – Struck by object due to collapse of building (ditto).

• W28 – Contact with powered lawn mower.

• W60 – Contact with nonvenomous plant thorns and spines and sharp leaves.

Master these. Future columns will cover injuries caused by forces of nature, injuries caused by supernatural means (such as witchcraft, exorcism), assassination (first episode, second episode, sequela), and acute psychosis caused by marauding ICD-10 consultants.

Dr. Rockoff practices dermatology in Brookline, Mass. He is on the clinical faculty at Tufts University School of Medicine, Boston, and has taught senior medical students and other trainees for 30 years. Dr. Rockoff has contributed to the Under My Skin column in Skin & Allergy News since January 2002.

As the date for implementing ICD-10 gets closer, consulting firms send daily offers to help us adapt to the new diagnostic regime. As a service to the profession, Under My Skin will provide periodic updates to save you consulting fees.

In an earlier column, you learned about new codes like injury from burning water skis. We also covered codes for envenomation by Gila monsters, both unintentional and intentional. You should know that these are already available under ICD-9. No need to wait till next year to use them!

ICD-9-CM E905.0: Venomous snakes and lizards causing poisoning and toxic reactions. These include the following: cobra, copperhead snake, coral snake, fer-de-lance snake, Gila monster, krait, mamba, viper, and several others. Do NOT use this code for bites by nonvenomous snakes and lizards. (That may come back to bite you ... Sorry!)

Anyone who can define a fer-de-lance or a krait is gets extra credit (but no extra payment). If you can either identify a mamba, or dance it, good for you!

ICD-10 naturally amplifies this inadequate taxonomy:

• T63.111 – Toxic effect of venom of Gila monster, accidental (unintentional)

• T63.112 – Toxic effect of venom of Gila monster, intentional (self-harm)

• T63.113 – Toxic effect of venom of Gila monster, assault

• T63.114 – Toxic effect of venom of Gila monster, undetermined

Questions: For the new "assault" code, was the Gila monster the assailant or was its owner? Does "undetermined" mean you don’t really know how you got bitten (come on, was that really an accident – weren’t you petting the Gila kind of roughly?) or that you didn’t determine whether it actually was a Gila monster (because it ran away so fast that that it could have been a marmoset).

There are other ICD-9 codes you can already use (right now!) I recently got a 6-page EMR from a referring clinic (you get those, don’t you?) listing one of the patient’s 14 diagnoses as E968.2: Assault by striking by blunt or thrown object.

This opened my eyes to:

• E968.5 – Assault by transport vehicle.

• E968.3 – Assault by hot liquid.

• E968.1 – Assault by pushing from a high place. (Questions: How high? How hot? Transporting what?)

While on the subject of injuries in high places, you might consider:

• E840.1 – Accident by powered aircraft at takeoff or landing.

Again, ICD-10 will be more comprehensive.

Looking at injury from burning water skis, we find:

• V91.07 – Burn due to water-skis on fire.

Within which are:

• V91.07XA ... initial encounter.

• V91.07XD ... subsequent encounter.

• V91.07XS ... sequela.

This is not all! V91.07 has many other subcategories:

• V91.0 – Burn due to watercraft on fire.

• V91.01 – Burn due to passenger ship on fire.

• V91.02 – Burn due to fishing boat on fire.

• V91.05 – Burn due to canoe or kayak on fire.

But wait! There is also V91.1 – Crushed between watercraft and other watercraft or other object due to collision. Within which are:

• V91.10 – Crushed between merchant ship and other watercraft or other object due to collision.

• V91.12 – Crushed between fishing boat and other watercraft or other object due to collision.

• V91.15 – Crushed between canoe or kayak and other watercraft or other object due to collision.

Each of these of course includes subcodes for: initial encounter, subsequent encounter, and sequela. (Conversion hysteria caused by paranoid fear of rampaging kayaks?)

The practical advantages to learning all this extend beyond the office. Suppose you’re fishing in a rowboat on a lazy Sunday afternoon when a kayaker waving a flaming blowtorch careens toward you full tilt and you leap overboard. When the Coast Guard pulls you out, you can shout, "V91.05! V91.15!"

In our next installment, we will take up other subsets of external causes of morbidity, including:

• W20 – struck by thrown, projected, or falling object such as:

• W20.0 – Falling object in cave (initial encounter, subsequent encounter, sequela).

• W20.1 – Struck by object due to collapse of building (ditto).

• W28 – Contact with powered lawn mower.

• W60 – Contact with nonvenomous plant thorns and spines and sharp leaves.

Master these. Future columns will cover injuries caused by forces of nature, injuries caused by supernatural means (such as witchcraft, exorcism), assassination (first episode, second episode, sequela), and acute psychosis caused by marauding ICD-10 consultants.

Dr. Rockoff practices dermatology in Brookline, Mass. He is on the clinical faculty at Tufts University School of Medicine, Boston, and has taught senior medical students and other trainees for 30 years. Dr. Rockoff has contributed to the Under My Skin column in Skin & Allergy News since January 2002.

As the date for implementing ICD-10 gets closer, consulting firms send daily offers to help us adapt to the new diagnostic regime. As a service to the profession, Under My Skin will provide periodic updates to save you consulting fees.

In an earlier column, you learned about new codes like injury from burning water skis. We also covered codes for envenomation by Gila monsters, both unintentional and intentional. You should know that these are already available under ICD-9. No need to wait till next year to use them!

ICD-9-CM E905.0: Venomous snakes and lizards causing poisoning and toxic reactions. These include the following: cobra, copperhead snake, coral snake, fer-de-lance snake, Gila monster, krait, mamba, viper, and several others. Do NOT use this code for bites by nonvenomous snakes and lizards. (That may come back to bite you ... Sorry!)

Anyone who can define a fer-de-lance or a krait is gets extra credit (but no extra payment). If you can either identify a mamba, or dance it, good for you!

ICD-10 naturally amplifies this inadequate taxonomy:

• T63.111 – Toxic effect of venom of Gila monster, accidental (unintentional)

• T63.112 – Toxic effect of venom of Gila monster, intentional (self-harm)

• T63.113 – Toxic effect of venom of Gila monster, assault

• T63.114 – Toxic effect of venom of Gila monster, undetermined

Questions: For the new "assault" code, was the Gila monster the assailant or was its owner? Does "undetermined" mean you don’t really know how you got bitten (come on, was that really an accident – weren’t you petting the Gila kind of roughly?) or that you didn’t determine whether it actually was a Gila monster (because it ran away so fast that that it could have been a marmoset).

There are other ICD-9 codes you can already use (right now!) I recently got a 6-page EMR from a referring clinic (you get those, don’t you?) listing one of the patient’s 14 diagnoses as E968.2: Assault by striking by blunt or thrown object.

This opened my eyes to:

• E968.5 – Assault by transport vehicle.

• E968.3 – Assault by hot liquid.

• E968.1 – Assault by pushing from a high place. (Questions: How high? How hot? Transporting what?)

While on the subject of injuries in high places, you might consider:

• E840.1 – Accident by powered aircraft at takeoff or landing.

Again, ICD-10 will be more comprehensive.

Looking at injury from burning water skis, we find:

• V91.07 – Burn due to water-skis on fire.

Within which are:

• V91.07XA ... initial encounter.

• V91.07XD ... subsequent encounter.

• V91.07XS ... sequela.

This is not all! V91.07 has many other subcategories:

• V91.0 – Burn due to watercraft on fire.

• V91.01 – Burn due to passenger ship on fire.

• V91.02 – Burn due to fishing boat on fire.

• V91.05 – Burn due to canoe or kayak on fire.

But wait! There is also V91.1 – Crushed between watercraft and other watercraft or other object due to collision. Within which are:

• V91.10 – Crushed between merchant ship and other watercraft or other object due to collision.

• V91.12 – Crushed between fishing boat and other watercraft or other object due to collision.

• V91.15 – Crushed between canoe or kayak and other watercraft or other object due to collision.

Each of these of course includes subcodes for: initial encounter, subsequent encounter, and sequela. (Conversion hysteria caused by paranoid fear of rampaging kayaks?)

The practical advantages to learning all this extend beyond the office. Suppose you’re fishing in a rowboat on a lazy Sunday afternoon when a kayaker waving a flaming blowtorch careens toward you full tilt and you leap overboard. When the Coast Guard pulls you out, you can shout, "V91.05! V91.15!"

In our next installment, we will take up other subsets of external causes of morbidity, including:

• W20 – struck by thrown, projected, or falling object such as:

• W20.0 – Falling object in cave (initial encounter, subsequent encounter, sequela).

• W20.1 – Struck by object due to collapse of building (ditto).

• W28 – Contact with powered lawn mower.

• W60 – Contact with nonvenomous plant thorns and spines and sharp leaves.

Master these. Future columns will cover injuries caused by forces of nature, injuries caused by supernatural means (such as witchcraft, exorcism), assassination (first episode, second episode, sequela), and acute psychosis caused by marauding ICD-10 consultants.

Dr. Rockoff practices dermatology in Brookline, Mass. He is on the clinical faculty at Tufts University School of Medicine, Boston, and has taught senior medical students and other trainees for 30 years. Dr. Rockoff has contributed to the Under My Skin column in Skin & Allergy News since January 2002.

Medical Education Library

A supplement to Skin & Allergy News. This supplement was sponsored by Medicis, a division of Valeant Pharmaceuticals.

• Herpes Simplex Virus-1: Prevalence and Diagnosis
• HSL Treatment
• XERESE^® (acyclovir and hydrocortisone) Cream 5%/1%
• Summary and Conclusions
• INDICATION
• IMPORTANT SAFETY INFORMATION

Faculty/Faculty Disclosure

Joseph Fowler, MD
University of Louisville
Louisville, Kentucky

Dr. Fowler reported that he is a member of the speakers’ bureau for Valeant Pharmaceuticals and received compensation from Valeant for his assistance in developing the content of this article.

LINKS: Click Here for PDF.

Copyright © by Frontline Medical Communications Inc.

Medical Education Library

A supplement to Skin & Allergy News. This supplement was sponsored by Medicis, a division of Valeant Pharmaceuticals.

• Herpes Simplex Virus-1: Prevalence and Diagnosis
• HSL Treatment
• XERESE^® (acyclovir and hydrocortisone) Cream 5%/1%
• Summary and Conclusions
• INDICATION
• IMPORTANT SAFETY INFORMATION

Faculty/Faculty Disclosure

Joseph Fowler, MD
University of Louisville
Louisville, Kentucky

Dr. Fowler reported that he is a member of the speakers’ bureau for Valeant Pharmaceuticals and received compensation from Valeant for his assistance in developing the content of this article.

LINKS: Click Here for PDF.

Copyright © by Frontline Medical Communications Inc.

Medical Education Library

A supplement to Skin & Allergy News. This supplement was sponsored by Medicis, a division of Valeant Pharmaceuticals.

• Herpes Simplex Virus-1: Prevalence and Diagnosis
• HSL Treatment
• XERESE^® (acyclovir and hydrocortisone) Cream 5%/1%
• Summary and Conclusions
• INDICATION
• IMPORTANT SAFETY INFORMATION

Faculty/Faculty Disclosure

Joseph Fowler, MD
University of Louisville
Louisville, Kentucky

Dr. Fowler reported that he is a member of the speakers’ bureau for Valeant Pharmaceuticals and received compensation from Valeant for his assistance in developing the content of this article.

LINKS: Click Here for PDF.

Copyright © by Frontline Medical Communications Inc.